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ABSTRACT 
 
Sarah Whitney Renner: Metabolic characterization of mice lacking carbonic anhydrase III (Car3) 
(Under the direction of Jay Brenman) 
 
Carbonic anhydrases (CAs) are a family of enzymes that catalyze the reversible 
condensation of water and carbon dioxide to bicarbonate and a proton. While CA III shares 
homology with α-CA family members, it has only 0.16% of the catalytic activity compared to 
other CAs. Despite the abundance of CA III in many metabolic tissues that are able to store 
lipids, a physiological role for CA III is currently unclear. Since CA III is nutritionally regulated, 
we utilized mouse genetics to evaluate the possible role of CA III in metabolism. Even though 
we found no obvious differences in metabolic phenotypes of mice deficient in CA III, we 
eliminated a potential function: CA III is not required for de novo lipogenesis. The role of CA III 
continues to be elusive, however it remains to be seen what phenotypes CA III deficient mice 
have under abnormal laboratory conditions.  
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CHAPTER 1 – THE α-CARBONIC ANHYDRASES 
 
The α-carbonic anhydrase family members are structurally similar yet functionally diverse 
 Carbonic anhydrases (CAs) are metalloenzymes that catalyze the reversible carboxylation 
of water into carbonic acid, which dissociates into bicarbonate and protons: 
H2O + CO2 H2CO3 HCO3- + H+ 
Carbonic anhydrase II is one of the fastest enzymes known to man, with a kcat of 1.4 x 10
6 
s-1 (Supuran 2008). While carbon dioxide and oxygen can spontaneously interact to form 
bicarbonate, organisms in all life kingdoms use CAs to catalyze the reaction fast enough for 
buffering capabilities (Del Prete, Vullo et al. 2014). Carbonic anhydrase was originally identified 
for its necessary role in transporting CO2 from tissues into the blood as bicarbonate (Meldrum 
and Roughton 1933). Since the discovery and isolation of the first carbonic anhydrase in 1933 
(Meldrum and Roughton 1933), nearly 12,000 articles, reviews, and books have been written 
about carbonic anhydrases. Additionally since 1933, four evolutionarily distinct carbonic 
anhydrase gene families have been discovered: α-CA family (vertebrates), β-CA (bacteria, algae, 
and plants), γ-CA (archaea and some bacteria), and δ-CA (marine diatoms) (Supuran 2008). As 
of the completion of this manuscript, carbonic anhydrases are implicated in a large variety of 
functions: respiration, acid-base homeostasis, ion transport, taste preferences, ureagenesis, 
gluconeogenesis, and photosynthesis (Sly and Hu 1995) (Dodgson 1991, Shah, Rubbelke et al. 
2013, Patrikainen, Pan et al. 2014) (Badger and Price 1994, Lehenkari, Hentunen et al. 1998). 
 The α-CA family is comprised mostly, 13 out of the 16 isozymes, of active enzymes that 
contain a functional catalytic site. These active CAs are structurally very similar especially near 
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the active site, which is comprised of three histidine (His) residues coordinated to Zn2+ (Figure 
1.1) (Aggarwal, Boone et al. 2013). The rate-limiting step of carbonic anhydrase reactions is 
regenerating the active form of the enzyme, which requires a proton shuttle (Supuran 2008). 
Differences in amino acids near the active site, particularly around the shuttle lead to decreased 
carbonic anhydrase activity (Elder, Fisher et al. 2007). 
There are 16 unique isozymes of carbonic anhydrase in mammals found in the α-CA 
family (Supuran 2008). In order to have such a wide range of physiological functions, the 
subcellular localization of these proteins is diverse: eight localize to the cytosol, five are 
transmembrane or membrane bound, two localize to the mitochondria, and one is secreted 
(Supuran 2008). The remainder of this chapter will discuss activity of CA isozymes, tissue 
localization, and proposed function for all of the mammalian carbonic anhydrases.  
Cytosolic CAs 
CA II is essential for respiration, CA I assists but is not required 
CA I and CA II have a physiological role in transporting CO2 generated by tissues to the 
lungs for expulsion. CO2 diffuses across membranes into blood cells where both CA I and CA II 
hydrate the carbon dioxide into carbonic acid, which subsequently dissociates into protons and 
bicarbonate molecules. The protons bind to hemoglobin and bicarbonate diffuses out of the 
erythrocytes into the plasma for delivery to the lungs. Near the lungs, the reverse reaction occurs, 
and the bicarbonate from the plasma is converted back to CO2 via the CAs in the red blood cell, 
and the CO2 is expelled (Esbaugh and Tufts 2006, Frost 2014). In addition to red blood cells, CA 
I is located in the large intestine, eyes, sweat glands and adipose tissue, whereas CA II is 
expressed in at least one cell type of every organ/tissue (Sly and Hu 1995).  
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Even though CA I is the most abundant protein in erythrocytes after hemoglobin, it 
appears that CA II is more critical to maintaining cellular respiration (Edwards, Drummond et al. 
2000). Humans deficient in CA II have systemic issues balancing pH and respiration, highlighted 
by issues maintaining homeostasis in the kidneys, brain and bones, whereas humans with CA I 
mutations do not develop a disorder (Sly and Hu 1995, Shah, Bonapace et al. 2004). The 
difference in disease outcome can be explained by the difference in activity of the two carbonic 
anhydrases; the activity of CA II, with the kcat of 1.4 x 10
6 s-1 is about 85% higher than CA I, kcat 
= 2.0 x 105 s-1 (Supuran 2008). While other carbonic anhydrases or molecular pathways can 
compensate for a deficiency of CA I, CA II is required for normal function, likely because of its 
ubiquitous expression and high activity (Sly and Hu 1995). 
CA III has low activity and localizes to metabolic tissues 
 CA III is the slowest active enzyme in the α-CA family, with a kcat of 1.0 x 104 s-1. 
(Supuran 2008). It is highly abundant in white adipose, brown adipose, skeletal muscle, and 
liver. CA III can be post-translationally modified via S-glutathionylation in response to oxidative 
damage (Harju, Bootorabi et al. 2013). Little research has been published about its functionality; 
the leading hypothesis is that it is involved in metabolism due to its abundance in metabolic 
tissues. Subsequent later chapters will discuss CA III in much greater detail.  
CA VII is implicated in seizures, oxidative damage, and tissue specific cancers  
CA VII is a cytosolic CA that has a high catalytic activity, kcat of 9.5 x 10
5 s-1, which is 
similar to the fastest recorded enzyme, CA II (Supuran 2008). CA VII is expressed in the colon, 
liver, skeletal muscle, and brain (Frost 2014). CA VII knockout (KO) mice have a normal life 
span, reproductive success, and no obvious deleterious phenotypes. However, when subjected to 
high temperatures, they are protected from seizures (Ruusuvuori, Huebner et al. 2013). The top 
  
4 
hypothesis for this finding was that CA VII is responsible for providing the bicarbonate 
necessary for the ion transport that generates synchronous neuronal excitation typically seen in 
seizures (Ruusuvuori, Li et al. 2004, Ruusuvuori, Huebner et al. 2013). 
CAVII can also be S-glutathionylated, which is an early molecular response to oxidative 
damage. There are two cysteine residues that have been found to react with glutathione without 
affecting the activity of the enzyme (Truppo, Supuran et al. 2012). Additionally, it was found 
that CA VII protected against apoptosis in cells transfected with CA VII, indicating a possible 
role in oxidative damage (Monti, De Simone et al. 2017). 
In cancer, involvement of CA VII is tissue specific. CA VII is highly expressed in a 
variety of brain tumors; patients with CA VII negative tumors have a higher survival rate than 
those with CA VII expressed (Bootorabi 2011). However, in colorectal carcinomas, there is a 4-
fold decrease in CA VII mRNA expression, which correlates with disease progression and is also 
predictive of prognosis (Yang, Hu et al. 2015, Viikila, Kivela et al. 2016). CA VII’s specific 
molecular function in cancer is currently unclear. 
CA XIII has a moderate catalytic activity and is widely expressed 
 CA XIII has moderate catalytic activity, a kcat of 1.5 x 10
5 s-1 (Supuran 2008). It is widely 
distributed in both humans and mice. Specifically, CA XIII can be found in the thymus, small 
intestine, spleen, prostate, ovary, colon, and testis in humans and spleen, lung, kidney, heart, 
brain, skeletal muscle, and testis in mice (Lehtonen, Shen et al. 2004). Despite being discovered 
more than a decade ago as a unique CA isozyme, the physiological function of CA XIII is still 
unknown. 
  
5 
Cytosolic carbonic anhydrase related proteins (CA-RPs) 
CA-RPS are catalytically dead and implicated in central nervous function 
 The CA-related proteins, CA VIII, X, and XI, are catalytically dead. While they have a 
high degree of homology with other active carbonic anhydrases, they are missing one, two, or all 
of the histidines critical for zinc binding and anhydrase activity: His94, 96, and 119 (Nishimori, 
Vullo et al. 2013).  
 Despite the lack of any anhydrase activity, CA-RPs are still physiologically necessary. 
CA VIII knockout mice have no control of their body movement; their limbs have involuntary 
contractions that cause twisting movements that persist throughout their life span (Jiao, Yan et al. 
2005). A single nucleotide polymorphism was found in CA VIII of humans, which causes mild 
retardation as well as difficulty walking (Turkmen, Guo et al. 2009). Interestingly, CA VIII acts 
as a binding protein to regulate motor function: CA VIII regulates Ca2+ release from Purkinje 
cells (or motor coordination cells) located in the cerebellum, by binding to the inositol 1,4,5-
triphosphate (IP3) receptor, blocking its affinity for IP3 (Hirota, Ando et al. 2003). Less is known 
about CA X and XI, however both are expressed in different regions of the central nervous 
system in mice and humans (Okamoto, Fujikawa-Adachi et al. 2001, Aspatwar, Tolvanen et al. 
2010). While their precise function is unknown, they have very recently been found to bind and 
potentially assist surface expression of neurexins, proteins essential for synaptic function 
(Sterky, Trotter et al. 2017). These findings indicate that CA-RPs have functional roles outside 
of the carbonic anhydrase catalytic activity and can bind other proteins.  
CA XI and VIII have also been implicated in enhancing proliferation and growth of 
cancer cells in a variety of tissue types. CA XI and VIII are both up-regulated in gastrointestinal 
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cancer, and CA VIII is additionally up-regulated in lung and colorectal cancer (Morimoto, 
Nishimori et al. 2005, Aspatwar, Tolvanen et al. 2010).   
Membrane-associated CAs 
CA IV assists in respiration, sperm motility, and extracellular buffering of the CNS 
 CA IV is one of two GPI-anchored, glycosyl-phoshatiydyl-inositol, proteins in the α-CA 
family. It is also the only membrane-associated CA with high activity in humans, kcat 1.1 x 10
6 s-1 
(Supuran 2008). CA IV contributes to extracellular buffering in the central nervous system, and 
it has been shown to assist in bicarbonate and CO2 transport in lung, kidney, and in isolated cells 
from other tissues (Shah, Ulmasov et al. 2005, Waheed and Sly 2014). However its role in 
respiration and pH buffering do not seem critical for survival; CA IV knockout mice are viable 
and have normal urinary pH (Shah, Ulmasov et al. 2005). CA IV KO mice do produce smaller 
litters, however this seems due to problems with sperm motility (Shah, Ulmasov et al. 2005). CA 
IV KO males have less motile and slower sperm than WT males, as bicarbonate is a known 
regulator of sperm motility (Wandernoth, Raubuch et al. 2010, Wandernoth, Mannowetz et al. 
2015). CA IV has many different functions and it is unclear how they all relate to one another.  
CA IX elevates during hypoxia and regulates gastric homeostasis 
 CA IX is a moderately active membrane-associated CA, kcat = 3.8 x 10
5 s-1, that localizes 
to stomach, colon and pancreas (Hilvo, Rafajova et al. 2004, Supuran 2008). Hypoxia Factor 1, 
HIF-1, is a transcription factor that can regulate CA IX expression. Hypoxia is important in the 
development of cancerous cells, as they grow rapidly and are unable to maintain an adequate 
oxygen supply from the current vascularization and require initializing their own anaerobic 
metabolism for energy requirements (Benej, Pastorekova et al. 2014). During hypoxic events, as 
in cancerous tumors without adequate blood flow, CA IX expression is elevated (Benej, 
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Pastorekova et al. 2014). CA IX is highly expressed in cancers of several tissues where CA IX is 
not typically expressed: renal, lung, cervical, ovarian, esophageal, and breast carcinomas (Kallio, 
Hilvo et al. 2010). While the function of CA IX in cancer is unknown, it is likely promoting the 
growth of cancer in hypoxic conditions.  
Conversely, in stomach cancers, CA IX expression is decreased (Kallio, Hilvo et al. 
2010). However, this is likely due to the function CA IX plays in maintaining homeostasis in the 
stomach. CA IX deficiency in mice caused gastric hyperplasia and atrophy of gastric mucosa, 
which was exacerbated by a high salt diet (Leppilampi, Karttunen et al. 2005), indicating that CA 
IX is involved in maintaining proliferative homeostasis of gastric tissues (Gut, Parkkila et al. 
2002).  
CA XII also elevates during hypoxia and is required for fluid homeostasis 
 CA XII is another moderately active membrane associated CA, kcat of 4.2 x 10
5 s-1, that 
localizes to the kidney and appears to have a role in regulating fluid homeostasis (Halmi, 
Lehtonen et al. 2004) (Supuran 2008). Humans with loss-of-function mutations in CA XII have a 
cystic fibrosis-like disease with elevated sweat chloride levels, failure to thrive, lung disease, and 
dry mouth/tongue (Hong, Muhammad et al. 2015, Lee, Vecchio-Pagan et al. 2016). The 
mechanism for CA XII regulating appropriate levels of sweat and other fluids is currently not 
understood, but may involve regulation of ion transport/cotransport.   
CA XII is another hypoxia-induced membrane-associated protein that is important in 
cancers. CA XII is highly expressed in renal cell carcinoma, esophageal squamous cell 
carcinoma, and in chemo-resistant cells of colorectal cancer. (Tureci, Sahin et al. 1998, Kopecka, 
Campia et al. 2015, Kopecka, Rankin et al. 2016). In esophageal cancer, CA XII serves as a 
prognostic tool-patients with a higher expression of CA XII in tumorous cells had a significantly 
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lower survival rate (Kopecka, Campia et al. 2015, Kopecka, Rankin et al. 2016). Similar to CA 
IX, the function of CA XII in cancer is unclear, but likely involved in promoting growth of 
tumor cells in the hypoxia observed in tumors.   
CA XIV promotes retinal light response and extracellular buffering in the brain 
 CA XIV also has moderate activity, kcat of 3.1 x 10
5 s-1, and has been found in isolated 
cell types in the brain, kidney, liver, colon, retina, heart, and skeletal muscles (Whittington, 
Grubb et al. 2004, Supuran 2008). The CA XIV knockout had a significant decrease in retinal 
light response, indicating that CA XIV plays an important functional role in signaling of the 
photoreceptors of the eye (Ogilvie, Ohlemiller et al. 2007). CA XIV also contributes to the 
buffering of the extracellular space in the brain (Shah, Ulmasov et al. 2005).  
Humans and chimpanzees evolved without CAXV 
 CA XV is the most recently discovered CA and little is known about its function. It is the 
only α-CA found to date that is not expressed in humans or chimpanzees; instead, these 
organisms have orthologues of non-functional pseudogenes (3 in humans and 2 in chimpanzees) 
that contain frame-shifts, insertions, or point mutations. Initial phylogenetic studies suggest CA 
XV is closely related to CA IV. Like CA IV, CA XV is a GPI-anchored protein located on the 
plasma membrane and is predominantly localized to the kidney. The CO2 hydration rate of 
human CA IV is 10-fold higher than mouse CA IV (Waheed and Sly 2014). It is likely that 
evolution equipped humans and chimpanzees with a much more efficient CA IV and they no 
longer required the moderate CA XV activity (kcat of 4.7 x 10
5 s-1 in mice) for bicarbonate 
buffering in the kidney (Hilvo, Tolvanen et al. 2005, Supuran 2008, Waheed and Sly 2014). 
Evolutionarily, transcription and translation of an enzyme that would only moderately assist in 
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activity could not be justified, especially if there is another enzyme that catalyzes the same 
reaction faster.  
Mitochondrial CAs 
CA VA & VB are required for ureagenesis 
There are two isoforms of the mitochondrial carbonic anhydrases, CA VA and CA VB, 
which until 1999 were considered the same isoform (Shah, Hewett-Emmett et al. 2000). 
Mitochondrial CAs have been implicated in providing the bicarbonate necessary for many 
metabolic pathways either directly (ureagenesis, gluconeogenesis) or indirectly (lipogenesis) 
(Figure 1.2) (Dodgson and Forster 1986, Lynch, Fox et al. 1995, Hazen, Waheed et al. 1996). In 
the mitochondria, carbamoyl phosphate 1 and pyruvate carboxylase require bicarbonate to 
catalyze the first committed steps of ureagenesis and gluconeogenesis (Lusty 1978, Jitrapakdee, 
St Maurice et al. 2008) Mitochondrial CAs are necessary to rapidly generate bicarbonate for any 
mitochondrial biochemical pathways, as bicarbonate cannot permeate the inner mitochondrial 
membrane (Arias-Hidalgo, Hegermann et al. 2016). Mitochondrial CA VA and VB indirectly 
affect lipogenesis, a cytosolic metabolic pathway, by regulating oxoaloacetate production 
through pyruvate carboxylase. Increasing or decreasing levels of oxoaloacetate allows regulation 
of citrate, which can then enter lipogenesis (Lynch, Fox et al. 1995, Hazen, Waheed et al. 1996, 
Jitrapakdee, St Maurice et al. 2008).  
CA VA is located primarily in the liver, skeletal muscle, and kidney. It has a moderately 
active kcat = 2.9 x 10
5 s-1, whereas CA VB is located more ubiquitously and has a faster kcat of 9.5 
x 105 s-1(Shah, Hewett-Emmett et al. 2000, Supuran 2008). CA VA deficiencies in humans result 
in hyperammonemia, or increased ammonia levels in the blood (van Karnebeek, Sly et al. 2014). 
To identify individual contributions of CA VA and CA VB, single and double knockout mice 
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were generated (Shah, Rubbelke et al. 2013). CA VA knockout mice weighed less and had 
higher levels of ammonia than WT, whereas CA VB KO mice had no observable phenotype. 
However, the phenotypes in the CA V double knockout mice were more severe than the CA VA 
single KO, indicating that, while CA VB single knockout has no phenotype, it still contributes to 
ureagenesis and other metabolic functions causing the decreased weight and higher levels of 
ammonia (Shah, Rubbelke et al. 2013). This suggests that while CA VB can contribute to 
ureagenesis and gluconeogenesis, it likely has a different primary functionality.  
Secreted CA 
CA VI affects taste perception and can contribute to cavity formation in teeth 
 Carbonic anhydrase VI is an abundant protein expressed in the submandibular gland (Sly 
and Hu 1995) (Frost 2014). Considered one of the main proteins secreted into saliva, the 
concentration of CA VI is 6.8 ± 4.3µg/ml in humans (Patrikainen, Pan et al. 2014). CA activity 
was discovered in human saliva in 1939, however CA VI was not identified as the isozyme until 
50 years later (Kivela, Parkkila et al. 1999). Human CA VI activity has a kcat of 3.4 x 10
5 s-1 
(Supuran 2008). Initial studies utilizing human populations to understand the function of CA VI 
were confounding. In human association studies, papers detailing taste perception contradicted 
each other as to whether CA VI polymorphisms affected bitter or salt perception (Padiglia, 
Zonza et al. 2010, Feeney and Hayes 2014). Mice deficient in CA VI were tested on taste 
preferences and were found to drink more quinine, a bitter flavor, and less salt, while 
maintaining the same amount of taste buds as their wildtype counterparts (Patrikainen, Pan et al. 
2014), indicating that CA VI assists in taste perception. 
 Additionally early research into the oral physiology of CA VI, indicated that CA VI 
protected against the formation of caries, or cavities (Kivela, Parkkila et al. 1999). However later 
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studies contradicted this hypothesis; mice deficient in CA VI were less susceptible to cavities 
than wildtype counterparts and children known to have cavities had higher CA VI activities in 
their saliva than children without (Culp, Robinson et al. 2011, Frasseto, Parisotto et al. 2012). 
The history of research into the function of CA VI highlights the importance of knockout mice in 
studying CAs, and how varied the phenotypes and functions can be.  
Using prior α-CA research to determine unknown functions of CAs 
Carbonic anhydrases are a diverse set of isozymes with a wide variety of physiological 
functions, from respiration to taste perception. Table 1.1 summarizes localization, catalytic 
activity, and proposed function for all isozymes of the α-CA family. We can utilize this CA 
knowledge of functionality as well as experimental methodology to aim our research at less 
understood CAs like CA III—the slowest carbonic anhydrase. 
For instance, mitochondrial CA VA and cytosolic CA III have overlapping tissue 
localizations. CA VA was found to provide the bicarbonate for mitochondrial metabolic 
pathways. Perhaps CA III provides bicarbonate for fatty acid synthesis, which occurs in the 
cytosol. Alternatively, CA VII and CA III can both be S-glutathionylated, and CA VII has been 
implicated in oxidative damage response. CA III could instead be assisting in response to 
damage, or it may contribute to both metabolism and oxidative damage. Many CAs have 
multiple seemingly unrelated functions, like CA IV-which functions in respiration, sperm 
motility, and extracellular buffering of the CNS,  
 Whatever the function of CA III, the evolution of CA XV to pseudogenes in humans and 
chimps suggests that if CA III had a duplicate function to one of the faster carbonic anhydrases, 
then CA III might be lost in evolution. This points to CA III having an alternative function 
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besides simply catalyzing the carboxylation of water. Since CA III has such a slow activity, it 
could instead act like the catalytically dead CA-RPs and bind proteins to alter function.   
 Studying the function of CAs is complex. Many carbonic anhydrases overlap in 
functionality and tissue localization so it is challenging to determine which CA is contributing to 
a specific function. Utilizing single and double knockout mice, researchers have been able to 
parse minor differences in carbonic anhydrases. This will help in guiding our research into 
understanding the function of CA III using a knockout mouse model in Chapter 3.  
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Figure 1.1. CA activity is reliant on an effective proton shuttle and hydrophobic binding 
pocket. (A) Active site of carbonic anhydrase, highlighted in purple, in the inactive form. (B) 
Under basic conditions, amino acids near the active site serve as proton shuttles that deprotonates 
the enzyme into the active form. (C) Carbon dioxide binds to a hydrophobic pocket near the 
active site and the reaction can begin. Adapted from (Supuran 2008).  
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Figure 1.2. Mitochondrial CA assists with ureagenesis, gluconeogenesis, and lipogenesis. 
Mitochondrial and cytosolic CAs are required to provide bicarbonate to metabolic pathways. 
Inset blue box: Bicarbonate cannot diffuse through mitochondria. Abbreviations: PC- pyruvate 
carboxylase, HCO3
-- bicarbonate, CA- carbonic anhydrase CPS1-carbamoyl phosphate 1, ACC- 
acetyl-CoA carboxylase, PEP- phosphoenolpyruvate. Adapted from (Dodgson and Forster 1986) 
(Hazen, Waheed et al. 1996) (Chegwidden, Dodgson et al. 2000) (Arias-Hidalgo, Hegermann et 
al. 2016).  
  
15 
Table 1.1. Localization, activity, and function of the α-CA family. 
Intracellular 
localization 
Isozyme 
Kcat (x 105) 
(s-1) 
Proposed functionality Main Tissue localization 
Cytosolic 
I 2 
• Respiration 
• Acid/base homeostasis 
colon, eye, sweat glands, 
adipose tissue, blood cells 
II 14 
• Respiration 
• Acid/base homeostasis 
ubiquitous 
III 0.1 
• Metabolism? 
• Oxidative damage? 
adipose tissues, skeletal 
muscle, liver 
VII 9.5 
• Seizures 
• Oxidative damage 
• Cancer 
Brain, colon, liver, and 
skeletal muscle 
XIII 1.5 • unknown 
lung, kidney, heart, brain, skeletal 
muscle, reproductive organs, 
intestines 
Cytosolic (CA-
RPs) 
VIII --- 
• Motor function 
• Proliferation of cancer 
brain 
X --- • CNS? Central nervous system 
XI --- 
• CNS? 
• Proliferation of cancer 
Central nervous system 
Membrane- 
associated 
IV 11 
• Respiration  
• Sperm motility 
• CNS buffering 
lung, kidney 
IX 3.8 
• Gastric homeostasis 
• Proliferation of cancer 
• Hypoxia? 
stomach, colon, pancreas 
XII 4.2 
• Fluid homeostasis 
• Proliferation of cancer 
• Hypoxia? 
kidney 
XIV 3.1 
• Photoreceptor signaling 
• CNS buffering 
brain and eyes 
mXV 4.7 • Unknown kidney 
Mitochondrial 
VA 2.9 
• Ureagenesis 
• Gluconeogenesis 
• lipogenesis 
liver, skeletal muscle, 
kidney 
VB 9.5 
• Ureagenesis 
• Gluconeogenesis 
• lipogenesis 
ubiquitous 
Secreted VI 3.4 
• taste perception 
• cavities in teeth 
salivary glands 
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CHAPTER 2 – PREVIOUS RESEARCH ON CARBONIC ANHYDRASE III 
 
Discovery of CA III 
CA III was originally identified as a unique carbonic anhydrase in 1978. The researchers 
who discovered CA III did not set out to study carbonic anhydrases, instead it was the “result of 
several years of frustrating search for the identity of an unknown protein” they found in their 
purification of phosphoglucose isomerase from skeletal muscle. CA III was a substantial by-
product of their purification that they labeled “basic muscle protein”, which they found 
“inconceivable at the time that a major component of solubilizable protein of skeletal muscle had 
not yet been identified” (Register, Koester et al. 1978). CA III is a very abundant protein in 
skeletal muscle comprising 1-2% of the total protein content (Register, Koester et al. 1978). 
The CA III Conundrum 
While CA III was originally identified in skeletal muscle of various animals, it was later 
found to be abundant in liver and adipose tissue of rodents (Shiels, Jeffery et al. 1984) (Spicer, 
Ge et al. 1990); CA III is highly abundant in these key metabolic tissues; it comprises 11% of the 
total protein and nearly 24% of cytosolic protein in rodent adipose tissue (Lynch, Brennan et al. 
1993). Compared to the other active enzymes in the α-CA family, CA III has a very low carbonic 
anhydrase activity, with a kcat ~1.0 x 10
4 s-1, or roughly 0.16% of the activity of CA II, despite 
having a 62% sequence identity in amino acids in humans (Nishimori, Minakuchi et al. 2007) 
(Nishimori, Minakuchi et al. 2009). (Tu, Chen et al. 1994) While it is not catalytically dead, like 
the CA-RP proteins, it is the least active α-CA.  
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The low activity of CA III is caused by critical differences in amino acids near the active 
site’s proton shuttle and hydrophobic binding pocket, Lysine 64 (K64) and Phenylalanine 198 
(F198). In 1989, Tu et al. discovered a crucial amino acid in the proton shuttle of CA II. By 
making a CA II H64A mutant, they caused a disruption and the activity of CA II was greatly 
decreased. In CA II, the proton shuttle, which regenerates the active form of the enzyme, is much 
more efficient than in CA III because it has a histidine instead of a lysine. Tu et al. showed that it 
was due to proton shuttling by measuring the activity of H64A CA II mutants in solutions 
buffered with imidazole (the proton donor in histidine) and found that it was similar to wildtype 
(Tu, Silverman et al. 1989). By creating a K64H CA III mutant, Jewell et al. tested whether CA 
III activity could be enhanced to be as fast as CA II. They found mutated K64H CA III had 
higher activity than wildtype CA III, but not as high as CA II (Jewell, Tu et al. 1991). 
To understand why CA III K64H was not as fast as CAII, more experimental mutations 
were made to CA II amino acids near the active site. The triple mutant CA III K64H R67N 
F198L, had a 500-fold increase in activity compared to wildtype CA III and had activities closer 
to wild type CA II (LoGrasso, Tu et al. 1991). Series of single and double mutants containing 
variants of K64, R67, and F198 allowed Tu et al. to determine that F198 was primarily 
responsible for the low activity of CA III (Tu, Chen et al. 1994). Through structural studies, it 
was determined that F198 in CA III resulted in a steric constriction near the hydrophobic binding 
pocket and thus altered interactions in the active site (Duda, Tu et al. 2005).  
In the field, it is a conundrum as to why CA III is so abundant in tissues, when it appears 
to not be a very effective carbonic anhydrase. Nearly thirty years ago, Edsall wrote “it is a 
puzzle, however, that the tissue cells make use of such a weakly enzyme to do this job…‘Why 
not the best?’ –in other words, carbonic anhydrase II, which is present elsewhere in the body. 
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Apparently, the gene for enzyme III was there, it was adequate for the job it had to do, and there 
was no sufficient pressure that might have produced a switch to a higher activity enzyme” 
(Edsall 1984). It has often been thought that maybe instead of acting as a carbonic anhydrase, 
CA III has a different physiological function. The rest of the chapter will delve into experiments 
that have further developed our understanding of the function of CA III. 
CA III knockout mice (Car3 KO) and controls respond similarly to common lab stressors 
To identify an alternative physiological function of CA III, a knockout mouse was 
generated, which will be referred to as Car3 KO or Car3 -/-. The Kim et al. paper describes the 
generation of the Car3 KO mouse on a 129SvEv background and also tests a variety of common 
phenotypes-growth, development, effects of stress, and life span (Kim, Lee et al. 2004). Growth, 
life span, and reproductive success were normal in the Car3 deficient mice. Car3 WT and KO 
mice contained similar levels of free fatty acids in serum, muscle, liver, and adipose tissue. No 
significant changes in mRNA were measured in their brain, kidney, liver, soleus, or 
gastrocnemius microarrays when comparing wild type and Car3 deficient mice. Kim et al. 
speculated as to why they found no significant phenotype: “it may be that Car3 is required for an 
effective response to specific stimuli or stresses which mice do not encounter in the laboratory 
animal facility” (Kim, Lee et al. 2004). Additionally, the 129SvEv background may have been 
problematic for discovering differences in metabolic phenotypes as this background is less likely 
to become glucose intolerant or develop fatty livers (Biddinger, Almind et al. 2005) (Champy, 
Selloum et al. 2008). Even after the generation of a KO mouse line, the function of CA III is still 
unknown. The next two sections of this chapter break down the knowledge of CA III into two 
focal points of past research: metabolism and oxidative damage.  
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CA III and metabolism 
CA III abundance decreases during starvation but increases when refed 
CA III protein and gene expression seem highly nutritionally regulated; it is down-
regulated in nutrient poor conditions and elevated in nutrient rich states. CA III gene expression 
is reduced in the muscle of starving mice after 24 hours by 1.7-fold, and further decreases to a 
2.4-fold reduction after 48 hours (Jagoe, Lecker et al. 2002). Even more striking is CA III 
mRNA expression in liver decreased 10-20-fold, after a 24 hour fast, and close to 60-fold 
decrease following a 48-hour starvation (Zhang, Xu et al. 2011) (Bauer, Hamm et al. 2004). 
Other nutritionally deficient conditions, protein depletion in the diet and chronic alcohol 
consumption, also decreased the expression of CA III protein and mRNA (Ronchi, Conde et al. 
2004) (Sanllorenti, Rosenfeld et al. 2001) (Caballero, Mendieta et al. 2011, Aroor, Roy et al. 
2012) (Kharbanda, Vigneswara et al. 2009, Yamada, Satoh et al. 2013, Carter, Vigneswara et al. 
2015). When refed after starvation, CA III mRNA levels increased to roughly half of the fed 
condition (Bauer, Hamm et al. 2004), which indicates that CA III responds to shifting dietary 
conditions and increases in nutrient-rich states. CA III protein and mRNA in both liver and white 
adipose tissue (WAT) also increased in rodents fed a high fat diet (Benard, Lim et al. 2016) 
(Bondia-Pons, Boque et al. 2011) (Mendez, Ciordia et al. 2017) (Van Schothorst, Franssen-van 
Hal et al. 2005).  
CA III expression correlates with changes in insulin  
The difference in CA III expression under fed/fasted states correlates with changes in 
insulin, a metabolic hormone critical to maintaining glucose homeostasis. Insulin and CA III 
expression are both elevated during the fed state and decreased under starvation (Bauer, Hamm 
et al. 2004). Additionally, in rats treated with streptozotocin, (STZ) a toxic drug targeted to 
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pancreatic islets that eliminates insulin production, CA III protein expression in liver decreased 
and CA III expression remained at normal levels when rats were given insulin after the STZ 
treatment (Nishita, Igarashi et al. 1995). This result implies that CA III expression responds to 
changes in insulin. Similarly, primary adipocytes treated with insulin increased CA III mRNA 
expression (Alver, Ucar et al. 2004). In nutrient rich states, insulin increases and stimulates the 
generation of new fatty acids in the cytosol. Because insulin and CA III expression are 
correlated, CA III could be providing the necessary bicarbonate for de novo fatty acid synthesis 
(Gibson, Titchener et al. 1958).  
CA III expression is lower in adipose tissue and livers of obese rodents 
Counter to the notion that CA III expression is high during nutrient rich state, there are 
rodent models of obesity that have decreased CA III expression compared to their lean siblings 
(Stanton, Ponte et al. 1991). While performing proteomic analysis to determine differences in 
ob/ob mice, Stanton et al. discovered that obese mice have decreased CA III protein and mRNA 
in WAT (Stanton, Ponte et al. 1991). Further proteomic analysis of other models of obesity, 
Zucker rats and NZO mice, confirmed that CA III decreases in WAT and liver of obese rodents 
(Lynch, Mccall et al. 1992) (Takahashi, Oh-Ishi et al. 2001) (Lynch, Brennan et al. 1993). 
However obese rodents still responded to starvation; in both lean and obese rodents, CA III 
mRNA decreased in WAT during fasting and increased upon refeeding (Stanton, Ponte et al. 
1991), indicating a role for CA III unique to the rodent models. These rodent models of obesity 
have impaired leptin signaling, a hormone secreted from adipose that assists in modulating food 
intake and energy expenditure (Wang, Chandrasekera et al. 2014) (Friedman and Halaas 1998). 
In addition to gaining weight, rodent models of obesity can also model type 2 diabetes (T2D) as 
they have dyslipidemia, mild hyperglycemia, and insulin resistance (Wang, Chandrasekera et al. 
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2014). This could indicate a role for CA III downstream of the leptin pathway or other pathways 
involved in obesity/T2D.   
CA III increases in adipose tissue of rosiglitazone treated mice  
T2D is characterized by impaired glucose homeostasis and insulin resistance (Lai, 
Chandrasekera et al. 2014). Rosiglitazone is a thiazolidinedione (TZD) drug used to treat 
diabetes by increasing insulin sensitivity. TZDs are agonists to the nuclear receptor, PPAR-γ, 
which regulates adipocyte differentiation as well as lipid storage. TZDs increase insulin 
sensitivity by promoting differentiation of adipocytes, fatty acid uptake, and decreasing the 
amount of lipids stored in an individual adipocyte. In TZD-treated patients and rodents, 
adipocytes are smaller and more numerous compared to untreated (Figure 2.1) (Johnson, Trasino 
et al. 2007, Quinn, Hamilton et al. 2008). Previous work from the Spiegelman group has shown 
that CA III mRNA increased in WAT of mice fed a high-fat diet and treated with rosiglitazone. 
As expected with rosiglitazone treatments, these mice gained weight and body fat, yet became 
more insulin sensitive (Choi, Banks et al. 2010) (Choi, Banks et al. 2011). This change in CA III 
abundance in response to rosiglitazone could be due to many different parameters- the decrease 
in insulin, the increase in adipocyte differentiation or fatty acid uptake, the increase in overall 
weight and body fat, or a response to elevated PPAR-γ.  
CA III may regulate adipogenesis through PPAR-γ 
To investigate the role of CA III in adipogenesis, Mitterburger et al. isolated primary, 
mouse embryonic fibroblasts, MEFs, from the Car3 WT and KO mice and differentiated them 
into adipocytes. CA III protein expression increased in the wildtype primary adipocytes during 
differentiation, however, in the knockout MEFs, the cells differentiated more quickly, had higher 
triglycerides and ~1000-fold increase in PPAR-γ mRNA. These results indicated that CA III can 
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regulate differentiation of adipocytes and lipid storage by directly or indirectly lowering PPAR-γ 
expression (Mitterberger, Kim et al. 2012). However, in 3T3 cell lines, a fibroblast cell line, cells 
transfected with CA III grew exponentially faster than the control transfections, indicating CA III 
was contributing to, not inhibiting, the growth of these cells (Raisanen, Lehenkari et al. 1999). 
The relationship between CA III and cell growth is unclear as there are few but conflicting 
studies. Further research using in vivo models could help better elucidate a role for CA III in 
adipogenesis and lipid accumulation.  
Skeletal muscles of Car3 knockout mice respond more slowly to stimuli 
 Muscle fatigue data from Car3 WT and KO mice further contributed indirect evidence to 
the hypothesis that CA III has a role in metabolism. The act of generating the mechanical energy 
necessary to move muscles requires ATP. ATP is initially generated in response to stimuli via 
phosphocreatine that is stored in locations that readily need access to quick sources of ATP: 
skeletal muscles, heart, and brain. Phosphocreatine donates its phosphate group to ADP in the 
surrounding muscle to quickly generate ATP (Wallimann, Wyss et al. 1992). After these short-
term stores of phosphocreatine are depleted, after 10-20 seconds, glycolysis, oxidative 
phosphorylation, and fatty acid oxidation are required to generate the ATP required to move 
muscles (Sahlin, Tonkonogi et al. 1998). In response to stimulation, Car3 WT and KO muscles 
reached the same levels of maximum recovery, however Car3 KO mice had a slower initial rate 
(Liu, Walter et al. 2007, Feng and Jin 2016). Real time analysis of phosphocreatine, ATP, and 
free phosphates in the muscles implied that while both Car3 WT and KO mice eventually 
generated enough ATP for maximal recovery, the Car3 KO mice had to utilize phosphocreatine 
ATP stores for slightly longer than WT mice. This implied that Car3 KO mice had impaired 
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regulation of alternative ATP producing pathways: glycolysis, oxidative phosphorylation, or 
fatty acid synthesis (Sahlin, Tonkonogi et al. 1998, Liu, Walter et al. 2007).  
CA III decreases during cold stress when fatty acid oxidation is high 
In addition to maintaining body temperature in cold conditions, brown adipose tissue 
(BAT), has the ability to take up and store fatty acids and glucose (Townsend and Tseng 2014). 
BAT has been implicated in maintaining a healthy weight and preventing metabolic disease 
(Harms and Seale 2013). During cold exposure, brown adipose tissues increase lipolysis of 
triglycerides and fatty acid oxidation to generate heat (Harms and Seale 2013). CA III mRNA 
decreased after prolonged exposure to cold temperatures in BAT of mice (Walden, Hansen et al. 
2012) (Forner, Kumar et al. 2009). This decrease in CA III in response to prolonged exposure in 
cold temperatures, hints at roles opposing fatty acid oxidation and promoting fatty acid uptake, 
lipid synthesis, or storage of lipids.   
CA III and oxidative damage 
CA III is S-glutathionylated in response to oxidative damage 
S-glutathionylation is a post-translational modification of the amino acid cysteine, where 
the sulfhydryl group of the cysteine binds to the sulfur-containing compound, glutathione (GSH). 
This modification is an early defense against oxidative damage in cells (Thomas, Poland et al. 
1995, Dalle-Donne, Rossi et al. 2009). In 1991, investigators were trying to identify the highly 
abundant, 30 kDa protein that was susceptible to S-glutathionylation in response to oxidative 
stress (Chai, Jung et al. 1991). They purified and identified the protein as CA III and determined 
that CA III has 3 forms: reduced, one cysteine S-glutathionylated, and two cysteines S-
glutathionylated. They were able to visualize the separate protein forms by using isoelectric 
focusing and incubating CA III with glutathione, to induce glutathionylation, or glutathione 
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disulfide, to reverse the glutathionylation (Chai, Jung et al. 1991). It was later confirmed by 
crystallography that two cysteine residues, 181 and 186, are both susceptible to S-
glutathionylation in CA III (Mallis, Poland et al. 2000) (Kim and Levine 2005).  
 Zimmerman et al. studied levels of S-glutathionylation in skeletal muscle of mice 
subjected to oxidative damage. By restricting blood flow and oxygen to the muscle of 
anesthetized mice, they found that CA III is increasingly S-glutathionylated during ischemic 
conditions (Zimmerman, Wang et al. 2004) Since CA III can be S-glutathionylated during 
oxidation, researchers have proposed CA III has a function in cellular response to oxidative 
damage (Dalle-Donne, Rossi et al. 2009). 
Superoxide dismutase KO mice have lower CA III in liver 
Superoxide dismutase (SOD) helps to protect cells against oxidative damage by quickly 
converting the harmful superoxide into peroxide, which can be broken down by other enzymes 
(Elchuri, Oberley et al. 2005). Younger SOD KO mice show no overt phenotypes, however, 
SOD KO mice have a shorter life span and their livers are more susceptible to many types of 
oxidative damage and spontaneously develop tumors (Elchuri, Oberley et al. 2005). While doing 
proteomic studies on SOD KO mice, Elchuri et al. determined that CA III protein and mRNA 
expression were lower in livers of SOD knockout mice and expression decreased with age 
(Elchuri, Naeemuddin et al. 2007). Additionally, they found that the amount of oxidized CA III 
protein was lower in SOD KO mice (Elchuri, Oberley et al. 2005). This further indicated that CA 
III could be involved in an oxidative damage response.   
Copper accumulation in the liver leads to decrease in CA III expression   
Wilson’s disease is a disorder in humans caused by mutations in a copper transporter that 
results in copper accumulations in the liver, brain, and eyes (Fuentealba and Aburto 2003). 
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Copper accumulation in the liver leads to oxidative damage through inflammation and fibrosis of 
the liver (Fuentealba and Aburto 2003). Both Wilson’s disease and a Wilson’s disease mouse 
model are characterized by an accumulation of copper in the liver; in mutant livers of mice, 
copper accumulates to about 800µg/g of liver, compared to 12µg/g in WT animals (Grimes, 
Paynter et al. 1997). Grimes et al. found CA III protein and mRNA levels decreased in the livers 
of these mutant mice. They also found CA III mRNA levels decreased in WT mice in response to 
copper injections, which confirmed the decrease in CA III expression was due to copper 
accumulation (Grimes, Paynter et al. 1997).  
CA III abundance decreases with hepatoxins associated with fatty liver disease 
While CA III abundance decreases in response to many different liver diseases (Figure 
2.2), these three different hepatoxic events –alcohol, protein deficiency, and carbon tetrachloride, 
can all be used to induce fatty liver disease in mice (Yamada, Satoh et al. 2013, Scholten, 
Trebicka et al. 2015, Kitade, Chen et al. 2017). Fatty liver disease progression has three main 
stages: accumulation of fat in the liver, inflammation and oxidative stress response to excess fat, 
fibrosis and cirrhosis of the liver (Kitade, Chen et al. 2017). The role of CA III in fatty liver 
diseases is not well understood; however, it could be contributing to the lipid dysregulation of 
the liver, the oxidative response to fat accumulation or both.  
CA III is one of the most down-regulated proteins and mRNAs in rodents fed alcohol, it 
decreased nearly 5-fold in the livers of rats chronically fed alcohol (Aroor, Roy et al. 2012) 
(Kharbanda, Vigneswara et al. 2009, Yamada, Satoh et al. 2013, Carter, Vigneswara et al. 2015). 
Chronic alcohol consumption can lead to liver damage through up-regulation of inflammation 
and oxidative stress, which eventually leads to steatosis and cirrhosis of the liver (Yamada, Satoh 
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et al. 2013). A decrease in CA III in response to chronic alcoholism implies that CA III may be a 
protectant against inflammation and steatosis as it decreases as liver damage increases.   
Protein depletion in the diet causes weight loss and susceptibility to infection and 
oxidative damage. Superoxide dismutase, a key protein that responds to oxidative damage, is 
down-regulated in the liver of mice during protein depletion, which leaves the liver vulnerable to 
oxidative damage. (Ronchi, Conde et al. 2004) (Sanllorenti, Rosenfeld et al. 2001). Protein 
depletion in mice decreased the total amount of all proteins in liver by 50%. CA III protein 
decreased by ~40% after protein depletion, and is one of the highest down-regulated proteins 
(Sanllorenti, Rosenfeld et al. 2001, Caballero, Mendieta et al. 2011).  
The decline in CA III in protein free diet fed mice can be rescued by supplementing with 
either methionine or cysteine (Ronchi, Conde et al. 2004). Methionine and cysteine are both 
sulfur-containing amino acids that can be involved in oxidative pathways as well as the 
development of fatty livers in mice (Brosnan and Brosnan 2006, Toohey 2014). Cysteine can 
often be a limiting factor for glutathione synthesis, a key antioxidant involved in S-
glutathionylation of proteins like CA III (Brosnan and Brosnan 2006). Cysteine is derived from 
methionine, so it is possible that the rescue of the CA III expression is due to the availability of 
cysteine and cysteine precursors (methionine) in the diet (Brosnan and Brosnan 2006), which 
allows for more S-glutathionylation of CA III and oxidative damage response.   
All hepatoxic events discussed so far have pointed to CA III being down-regulated during 
times of oxidative stress, however some hepatotoxic compounds like acetaminophen, 
amiodarone hydrochloride, tetracycline hydrochloride and carbon tetrachloride acutely increased 
protein expression of CA III in rodent livers 24 hours after treatment (Yamamoto, Kikkawa et al. 
2006). Yet, with prolonged exposure of carbon tetrachloride or large doses of acetaminophen, 
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CA III protein expression decreased; there was a 20-fold decrease of CA III in rats after 4 days 
of exposure to acetaminophen (Henkel, Roderfeld et al. 2006, Wong, Fan et al. 2011, Eakins, 
Walsh et al. 2015). This implies that CA III protein expression increases immediately in response 
to oxidative stress, but as it responds it is degraded quickly or is only necessary for the initial 
response to injury.  
CA III overexpression protects against apoptosis in cells subjected to oxidative damage  
Hypoxia, the deficiency of oxygen in tissues, and hydrogen peroxide, a common reactive 
oxygen species, can trigger oxidative damage to cells and tissues, which can result in the 
induction of apoptosis (Shang, Bao et al. 2012) (Raisanen, Lehenkari et al. 1999). In C2C12 and 
3T3 cell lines, CA III was overexpressed and oxidative stress was induced using either hypoxia 
or hydrogen peroxide (Shang, Bao et al. 2012) (Raisanen, Lehenkari et al. 1999). In both 
experiments, CA III overexpression significantly lowered the rate of apoptosis and in the 3T3 
cell line, the intracellular oxidation levels were lower in CA III transfected cells. This indicated 
that overexpression of CA III corresponded with lower levels of cell death possibly by protecting 
the cells from oxidative damage (Shang, Bao et al. 2012) (Raisanen, Lehenkari et al. 1999).  
Car3 KO mice were not affected by oxidative damage 
While CA III appears to protect against oxidative damage induced apoptosis in cell 
culture, Car3 deficiency in vivo does not affect oxidative damage. Hyperoxia, excess oxygen in 
tissues, induces oxidative damage. Car3 WT and KO mice were exposed to a 100% oxygen 
environment to induce hyperoxia and oxidative damage, no difference was found in survival 
between the genotypes (Kim, Lee et al. 2004). Car3 deficient soleus muscles, a slow-twitch 
skeletal muscle, behaved the same as wildtype muscles when subjected to a hypoxia challenge. 
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Both groups of mice had a similar internal pH, indicating the response to oxidative damage is not 
affected by Car3 deficiency (Liu, Walter et al. 2007). 
CA III expression drastically changes in response to many stimuli, but what is its function? 
Even before its discovery as a unique isozyme, CA III has been “frustrating” researchers 
for years, either as an unknown contaminant or now as a puzzling protein without a defined 
function (Register, Koester et al. 1978). Much of what is know about CA III’s role originates 
from proteomic studies of metabolic or oxidative damage stressors. From this research, we can 
glean that CA III expression changes in response to many different stressors (Figure 2.3), 
suggesting a physiological function in different molecular pathways.  
CA III is abundant in metabolic tissues that can store fat: liver, skeletal muscle and 
adipose tissues. Prior research implies a role for CA III in various pathways related to lipid 
metabolism: de novo lipogenesis, fatty acid uptake, lipid accumulation leading to fatty liver 
disease, and fatty acid oxidation. While dynamic regulation and tissue localization of CA III may 
suggest a novel function of CA III, the relationship between CA III and lipid metabolism has 
never directly been tested.  
CA III can also be post-translationally be modified via S-glutathionylation and 
consequently it has been suggested that CA III assists in the initial reaction to protect cells and 
tissues from oxidative damage. Accordingly, CA III expression responded to prolonged exposure 
of multiple stressors that promote oxidative cell damage. CA III also protected against oxidative 
damage induced apoptosis in vitro, however, in vivo studies with CA III KO mice indicated CA 
III was not critical for oxidative damage response. The conflicting in vitro and in vivo results 
makes the involvement of CA III in oxidative damage unclear. 
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Despite being discovered nearly 40 years ago, the function of the slowest CA, CA III, 
remains an enigma. The next chapter discusses how we further tested the role of CA III in 
metabolism in vivo.   
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Figure 2.1. Rosiglitazone treated mouse and human adipocytes are smaller, more 
numerous, and have increased expression of Car3. Top panel: Adipocyte morphology in 
untreated and treated diabetic mouse and human patients. Bottom panel: Graphical representation 
of key traits in rosiglitazone untreated and treated adipocytes. Adapted from (Johnson, Trasino et 
al. 2007) (Choi, Banks et al. 2010) (Choi, Banks et al. 2011). 
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Figure 2.2. CA III expression decreases in many different liver diseases. (A) Progression of 
fatty liver disease can be triggered through many stressors, and follows a two-hit model. (B) 
Wilson’s Disease in mice is caused by the mutation in copper transporter Tx. (C) Liver cancer 
can be modeled in SOD knockout mice as they develop tumors as they age. Adapted from  
(Kitade, Chen et al. 2017) (Anstee and Goldin 2006) (Grimes, Paynter et al. 1997, Fuentealba 
and Aburto 2003, Elchuri, Oberley et al. 2005). 
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Figure 2.3. CA III is highly abundant and dynamically expressed in metabolic tissues CA 
III is abundant in liver, white adipose tissue (WAT), brown adipose tissue (BAT), and skeletal 
muscle. CA III mRNA and protein expression changes in response to many different stimuli.  
  
34 
 
CHAPTER 3 – CARBONIC ANHYDRASE III (Car3) IS NOT REQUIRED FOR FATTY 
ACID SYNTHESIS AND DOES NOT PROTECT AGAINST HIGH-FAT DIET 
INDUCED OBESITY IN MICE1 
 
Summary 
Carbonic anhydrases are a family of enzymes that catalyze the reversible condensation of 
water and carbon dioxide to carbonic acid, which spontaneously dissociates to bicarbonate. 
Carbonic anhydrase III (Car3) is nutritionally regulated at both the mRNA and protein level. It is 
highly enriched in tissues that synthesize and/or store fat: liver, white adipose tissue, brown 
adipose tissue, and skeletal muscle. Previous characterization of Car3 knockout mice focused on 
mice fed standard diets, not high-fat diets that significantly alter the tissues that highly express 
Car3. We observed lower protein levels of Car3 in high-fat diet fed mice treated with 
niclosamide, a drug published to improve fatty liver symptoms in mice. However it is unknown 
if Car3 is simply a biomarker reflecting lipid accumulation or whether it has a functional role in 
regulating lipid metabolism. We focused our in vitro studies toward metabolic pathways that 
require bicarbonate. To further determine the role of Car3 in metabolism, we measured de novo 
fatty acid synthesis with in vitro radiolabeled experiments and examined metabolic biomarkers in 
Car3 knockout and wild type mice fed high-fat diet. Specifically, we analyzed body weight, body 
composition, metabolic rate, insulin resistance, serum and tissue triglycerides. Our results 
                                                 
1 This chapter previously appeared as an article in PLoS One. The original citation is as follows: 
Renner, S. W., L. M. Walker, L. J. Forsberg, J. Z. Sexton and J. E. Brenman (2017). "Carbonic 
anhydrase III (Car3) is not required for fatty acid synthesis and does not protect against high-fat 
diet induced obesity in mice." PLoS One 12(4): e0176502. 
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indicate that Car3 is not required for de novo lipogenesis, and Car3 knockout mice fed high-fat 
diet do not have significant differences in responses to various diets to wild type mice.  
Introduction 
Carbonic anhydrases (CAs) are isozymes that catalyze the carboxylation of water into 
carbonic acid, which spontaneously dissociates into bicarbonate and protons (H2O + CO2 
H2CO3 HCO3- + H+) (Meldrum and Roughton 1933, Lindskog and Silverman 2000). There 
are 16 unique isozymes in the vertebrate carbonic anhydrase gene family, or the α-CA family 
(Supuran 2008). Carbonic anhydrases are involved in a wide variety of functions: respiration, 
acid-base homeostasis, ion transport, bone resorption, taste preferences, ureagenesis and 
gluconeogenesis (Dodgson 1991, Sly and Hu 1995, Lehenkari, Hentunen et al. 1998, Shah, 
Rubbelke et al. 2013, Patrikainen, Pan et al. 2014). The subcellular localization of these proteins 
is diverse: eight localize in the cytosol, five are transmembrane or membrane bound, two localize 
to the mitochondria, and one is secreted (Supuran 2008).  The α-CA family is comprised of 
active enzymes that contain a functional catalytic site (CA I, II, III, IV, VA, VB, VI, VII, IX, 
XII, XIII, XIV, XV) as well as catalytically dead enzymes known as carbonic anhydrase related 
proteins (CA-RP VIII, X and XI) (Supuran 2008). While most of the active carbonic anhydrases 
have some of the highest activity rates in biology, CA III has 0.16% of the activity compared to 
CA II (Chegwidden and Carter 2000, Nishimori, Minakuchi et al. 2009). Unlike the CA-RP 
proteins, which have mutated histidine (His) residues in the active catalytic site leaving them 
enzymatically inactive, CA III still maintains the histidine site for CAs, containing a zinc 
molecule surrounded by three His residues (Nishimori, Minakuchi et al. 2007, Supuran 2008, 
Aspatwar, Tolvanen et al. 2014). However, CA III does differ in amino acid alignment with the 
closely related CA I and CA II proteins at two important residues, as depicted in (Figure 3.1), 
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lysine 64 (Lys) and phenylalanine 198 (Phe), which dramatically decrease the activity of CA III 
(LoGrasso, Tu et al. 1993, Tu, Chen et al. 1994, An, Tu et al. 2002, Duda, Tu et al. 2005, Elder, 
Fisher et al. 2007). While the function of CA III is currently unknown it has been speculated to 
be involved in metabolism, oxidative damage response, and mitochondrial ATP synthesis 
(Raisanen, Lehenkari et al. 1999, Alver, Ucar et al. 2004, Zimmerman, Wang et al. 2004, Liu, 
Walter et al. 2007, Mitterberger, Kim et al. 2012) 
 CA III (Car3 in mice) is highly abundant in tissues that can store lipids in mice: liver, 
brown fat and white adipose tissues (approximately 24% of soluble protein in white adipose), 
and slow-twitch skeletal muscle (Lynch, Brennan et al. 1993). Car3 appears to be nutritionally 
regulated; during starvation Car3 mRNA decreases in rodent livers (Dodgson, Quistorff et al. 
1993, Bauer, Hamm et al. 2004, Zhang, Xu et al. 2011) and Car3 mRNA subsequently increases 
upon refeeding. Car3 protein expression also increases in rodents fed Western-type high fat diets 
in both livers (31-83% increased protein) and white adipose tissue (97-129% increased mRNA) 
(Van Schothorst, Franssen-van Hal et al. 2005, Bondia-Pons, Boque et al. 2011, Mendez, Ciordia 
et al. 2017) Additionally, dietary stressors on rodents, including protein depletion and alcohol 
consumption, decrease the mRNA and protein levels of Car3 in the liver. (Sanllorenti, Rosenfeld 
et al. 2001, Ronchi, Conde et al. 2004, Kharbanda, Vigneswara et al. 2009, Caballero, Mendieta 
et al. 2011, Aroor, Roy et al. 2012, Yamada, Satoh et al. 2013, Carter, Vigneswara et al. 2015). 
Car3 expression also changes in response to insulin, a key metabolic hormone. Car3 mRNA 
expression increases in response to insulin in adipose tissue (Alver, Ucar et al. 2004) and Car3 
protein decreases in liver when insulin is decreased in rats through injection of streptozotocin 
(Dodgson and Watford 1990, Nishita, Igarashi et al. 1995). Since de novo lipogenesis occurs 
during nutrient-rich states when insulin levels are high (Mabrouk, Helmy et al. 1990), and there 
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is the requirement of bicarbonate substrate in the committed step of fatty acid synthesis, acetyl-
Coa  malonyl-CoA, (Gibson, Titchener et al. 1958), we hypothesized that carbonic anhydrase 
III is providing the necessary bicarbonate for de novo lipogenesis. CAs that are highly 
enzymatically active have been suggested to provide the bicarbonate for de novo lipogenesis; 
animals and cells with pharmacologically decreased CAs have decreased de novo lipogenesis 
(Herbert and Coulson 1984, Lynch, Fox et al. 1995, Hazen, Waheed et al. 1996), but the role of 
Car3, with much lower enzymatic activity, in de novo lipogenesis has not been previously 
studied.   
In rodent models of diabetes/obesity, Car3 protein expression in liver and/or adipose 
tissue decreases in obese Zucker rats and in ob/ob mice compared to wild type rodents (Stanton, 
Ponte et al. 1991, Lynch, Mccall et al. 1992, Lynch, Brennan et al. 1993). Even though Car3 may 
decrease, acetyl Co-A carboxylase (ACC) protein expression is up-regulated in adipose tissue of 
obese Zucker rats (Lynch, Mccall et al. 1992), perhaps contradictory with a role for Car3 in de 
novo lipogenesis.  
The small molecule drug Niclosamide (Nicl) has recently been implicated as a potential 
therapeutic for type 2 diabetes (T2D) and fatty liver disease in mice fed HFD (Tao, Zhang et al. 
2014, Chowdhury, Turner et al. 2017). Niclosamide prevents insulin resistance in high-fat diet 
fed mice, and improves insulin sensitivity in db/db mice, a leptin signaling deficient rodent 
model (Tao, Zhang et al. 2014, Wang, Chandrasekera et al. 2014). Excess storage of lipids in 
liver, adipose, and muscle tissues contributes to T2D, and mice treated with niclosamide have 
reduced fat accumulation in liver and decreased liver triglycerides in a fatty liver mouse model 
(Tao, Zhang et al. 2014). In this study, we used two-dimensional differential gel electrophoresis 
(2D-DIGE) to identify Car3 as a protein highly expressed in DIO mice with fatty liver, but 
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down-regulated in DIO mice treated with niclosamide. This result suggests that Car3 may reflect 
the lipid content of tissues. 
To determine whether Car3 has a functional role in lipid content we characterized the 
previously described Car3 -/- mice (Kim, Lee et al. 2004). No obvious deleterious phenotypes 
have been reported in previous studies on Car3 knockout mice; however, the affect of specialized 
diets on these knockout mice was not previously researched (Kim, Lee et al. 2004, Zimmerman, 
Wang et al. 2004, Liu, Walter et al. 2007, Mitterberger, Kim et al. 2012, Feng and Jin 2016). In 
this study, we investigate Car3 function in de novo lipogenesis by measuring fatty acid synthesis 
in isolated mouse hepatocytes, and during induced obesity through high-fat diet by measuring 
subsequent changes in body weight, dyslipidemia, insulin resistance, food intake, and energy 
expenditure.  
Materials and Methods 
2D-DIGE protocol and western blot confirmation animal Care  
20-week old diet-induced obesity (DIO) mice were purchased from Jackson Labs, with 
mice starting on the high-fat diet (D12492, Research Diets) at 6 weeks. At 20 weeks of age, mice 
were treated with 10mg/kg niclosamide or DMSO vehicle control for 12 days by daily 
intraperitoneal (IP) injections. Mice were harvested to obtain liver tissue. Mice were maintained 
at the University of North Carolina (UNC) under protocols specifically approved for this study 
by the UNC Institutional Animal Care and Use Committee (IACUC). 
2D-Differential Gel Electrophoresis (2D-DIGE) of niclosamide-treated mouse liver 
 Liver lysates were prepared, and 2D-DIGE experiments performed by the University of 
North Carolina Systems-Proteomics Center core facility as previously described (Osorio, 
Sullivan et al. 2007, Onyenwoke, Forsberg et al. 2012). Protein spots were identified using 
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peptide mass fingerprinting tandem mass spectrometry data by the Yale Mass Spectometry and 
Proteomics Resource Core (New Haven, CT), according to previously described methods 
(Osorio, Sullivan et al. 2007, Pinaud, Osorio et al. 2008, Onyenwoke, Forsberg et al. 2012). 
Western blotting of mouse liver lysates 
20 week old DIO high-fat diet fed mice were treated for 12 days with either 5 mg/kg, 25 
mg/kg niclosamide, or DMSO (vehicle) by daily IP injections (40 µl). On the last day of 
treatment, mice were sacrificed and livers harvested and frozen on dry ice. For western blot 
analysis, liver samples were homogenized and sonicated in 10 volumes of RIA lysis buffer (50 
mM Tris-Cl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 1 
mM PMSF, 1 mM beta-glycerolphosphate, 2.5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 1X Sigma-Aldrich P8340 protease inhibitor cocktail). Homogenates were 
clarified by centrifugation at 16,000xg for 10 minutes at 4°C, and protein in the supernatant was 
quantified using the Bio-Rad Dc Assay (Hercules, CA). Protein samples in loading buffer (Life 
Technologies NP0007) were loaded at 50 µg per well on 4-12% NuPAGE gels and separated for 
45 minutes at 200V, then transferred to Immobilon-FL blotting membrane at 300 mA for 1 hour. 
Blots were blocked with 5% milk in TBS, then probed for carbonic anhydrase III (Santa Cruz 
Biotechnology, sc-50715) and subsequently actin (MP Biomedicals, #69100) to control for total 
protein loaded. Secondary antibodies were (IRDye infrared antibodies, LI-COR Biosciences, 
Lincoln, NE) (Onyenwoke, Forsberg et al. 2012). The Odyssey Infrared Imaging System was 
used for quantification of the relative intensity ratio of Car3/Actin (LI-COR Biosciences, 
Lincoln, NE). 
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Animal Care for Car3 knockout mice  
Car3 -/- mice were obtained from NIH (kind gift from Dr. Levine) on a mixed 129SvEv 
background as previously generated (Kim, Lee et al. 2004). To outcross the Car3 knockout 
alleles into a C57BL/6J background more appropriate for metabolic studies (Almind and Kahn 
2004, Andrikopoulos, Massa et al. 2005, Berglund, Li et al. 2008), male progeny were 
backcrossed with C57BL/6J female at least 8 generations. Sibling matched males were used in 
all analyses, unless otherwise specified. Mice were weaned at 3-4 weeks of age and placed on 
standard chow (2020X, Teklad Diets, Madison WI). Mice were maintained at the University of 
North Carolina under protocols specifically approved for this study by the UNC IACUC. 
Hepatocyte isolation and de novo lipogenesis assays 
Hepatocytes were isolated using a protocol adapted from Wendel et al. (Wendel, Cooper 
et al. 2013). Littermate female mice fed standard chow were anesthetized by IP injection of 
250mg/kg tribromoethanol.  Once mouse toes were unresponsive to touch, a 24G catheter was 
inserted into the portal vein. The liver was perfused with Perfusion Buffer 1 (115mM NaCl, 
25mM HEPES, 5mM KCl, 1mM KH2PO4, 525µM EGTA, pH 7.4) warmed to 37°C, and then 
Perfusion Buffer 2 (115mM NaCl, 25mM HEPES, 5mM KCl, 1mM KH2PO4, 2.5mM MgSO4, 
1.6mM CaCl2, 1.4-1.8mg/ml collagenase Type I (Worthington Chemicals, Lakewood, NJ), pH 
7.4) warmed to 37°C. After perfusion was complete, the liver was excised and hepatocytes were 
released by gently tearing the liver lobes in chilled Isolation Medium, DMEM (Gibco #31053-
028), 5% Fetal Bovine Serum, 1% Penicillin/Streptomycin, 2mM L-Glutamine, 1x MEM Non-
Essential Amino Acids, 4µg/ml insulin, 0.1µM Dexamethasone. The hepatocytes were then 
filtered through a 100µm cell strainer and centrifuged at 50 x g for 2 min at 4°C. The cells were 
washed twice with cold Isolation Medium, and resuspended in warmed Isolation Medium for cell 
  
41 
counting and plating. Hepatocytes were plated on collagen-coated 6-well dishes with 1x106 cells 
per well, and incubated at 37°C with 5% CO2. After cells attached to the plates (4 h post-
plating), media were changed to warmed L-15 media with 1% penicillin/streptomycin. Sixteen to 
20 h after plating, hepatocytes were rinsed with warmed 1x PBS, (Gibco #14190-144) and then 
treated with 2ml of Assay Medium, L15 media (Gibco #11415-064), 1% penicillin/streptomycin, 
0.8µCi/ml [1,2-14C] acetic acid (Perkin Elmer Life Sciences, NEC553001MC) for 2 hours. The 
hepatocytes were rinsed with warmed 1x PBS, and then lysed with methanol and scraped. Lipids 
were extracted from hepatocyte lysates using water:chloroform:methanol (0.8:2:2 v/v/v). Lipids 
from the chloroform layer were collected, dried down, and counted in scintillation vials. Protein 
quantifications were made using duplicate plates from the same hepatocyte isolation. Cells were 
scraped and sonicated in SDS lysis buffer (2% SDS, 60mM Tris-Cl pH 6.8, 1mM PMSF, 2.5 
mM sodium pyrophosphate, 1mM beta-glycerolphosphate, 1mM sodium orthovanadate, 1X 
Sigma-Aldrich P8340 protease inhibitor cocktail). Cell lysates were clarified by centrifugation at 
16,000xg for 10 minutes at 4°C, and protein in the supernatant was quantified using the Bio-Rad 
Dc Assay (Hercules, CA). 
Metabolic characterization of mice on high fat diet 
At 5-6 weeks of age, mice either remained on standard chow or were placed on a high-fat 
diet (Almind and Kahn 2004, Winzell and Ahren 2004, Wang and Liao 2012). The standard 
chow caloric consumption is 24 kcal% protein, 16 kcal% fat, and 60 kcal% carbohydrate, and the 
energy density is 3.1 kcal/g food (2020X, Teklad Diets, Madison WI). The high-fat diet caloric 
consumption is 20 kcal% protein, 60 kcal% fat, and 20 kcal% carbohydrate, and the energy 
density is 5.24 kcal/g food (D12492, Research Diets, New Brunswick, NJ). 
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Metabolic chambers and body composition 
Mouse body composition, energy expenditure, activity, and food intake were measured at 
the Animal Metabolism Phenotyping Core at UNC under the supervision of Dr Kunjie Hua. 
Body composition was determined by MRI at 11 weeks of age (EchoMRI, Houston, TX) (Nixon, 
Zhang et al. 2010). Energy expenditure, activity, and food intake were measured at 13-14 weeks 
of age using CaloCages (PhenoMaster, TSE systems, Chesterfield, MO). Data were collected for 
2 days; the first day was considered the acclimation period and was excluded from data analysis 
(Cooper, Grevengoed et al. 2015). Mice had unlimited access to food and water for the entire 
duration in metabolic chambers.  
Serum measurements  
Fasted mice were starved overnight (15-16 hours) (Champy, Selloum et al. 2004) and 
measurements were taken at the beginning of the light cycle. To better synchronize the feeding 
schedule for fed measurements, food was removed from the cages during the light cycle, and 
mice were fed ad libitum during the dark cycle. Fed measurements were taken at the beginning 
of the light cycle after three nights of entrainment as described (Wang, Quagliarini et al. 2013). 
Glucose was measured with a drop of whole blood using a glucometer (Bayer Contour, 
Leverkusen, Germany). Whole blood was collected from mice using Microvette® tubes 
(CB300Z, Sarstedt, Nümbrecht, Germany) under fasting and fed conditions. To extract serum 
from whole blood, the blood was allowed to clot for 30-90 min at room temperature and then 
centrifuged at 2000 x g for 20 min (4°C), per provided instructions from Microvette. Insulin 
levels were determined using a mouse insulin ELISA kit (Crystal Chem Inc, Downers Grove, 
IL). Serum triglycerides (Wako Diagnostics, Richmond, VA), non-esterfied fatty acids (Wako 
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Diagnostics, Richmond, VA), cholesterol (Stanbio, Boerne, TX) and glycerol (Sigma-Aldrich, 
St. Louis, MO) were determined with enzymatic colorimetric assays.  
Oral glucose tolerance test (GTT) 
Sixteen-week-old mice were fasted overnight for 14-15 hours followed by oral gavage of 
2 mg/g body weight of glucose. Blood glucose was measured at 0, 15, 30, 60, and 120 minute 
time points using a glucometer, as described previously described (Ayala, Samuel et al. 2010, 
Deol, Evans et al. 2015).  
Tissue triglycerides 
At 18 weeks of age, mice were sacrificed and tissues were weighed and collected for 
further analysis. Liver triglycerides were measured from the left lobe, while muscle triglycerides 
were measured from calf muscle using a protocol adapted from (Zagani, El-Assaad et al. 2015). 
Tissues were homogenized on ice using the BeadBug (Benchmark Scientific, Edison, NJ) with 
50-100 mg of tissue in 10 or 20 volumes of 5% NP-40 in water (10 volumes for liver samples 
and 30 volumes for muscle samples). Samples were boiled @ 100°C for 5 min, then cooled to 
room temperature twice. The samples were then centrifuged at 16,000 x g for 2 min to pellet 
denatured DNA and proteins. Supernatants were then used to measure triglycerides using a 
colorimetric assay (Sigma-Aldrich, St. Louis, MO).  
Body temperature and thermoregulation 
Body temperatures from mice fed standard or high-fat diet were measured by rectal probe 
under fasting (15-18 hours) and fed (ad libitum) conditions (MicroTherma 2, ThermoWorks, 
American Fork, UT) (Dubuc, Wilden et al. 1985). Adult female mice, 8-13 weeks of age, were 
fasted overnight and exposed to 4°C for 5 hours (Putri, Syamsunarno et al. 2015).  
Statistics 
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All data and statistics were analyzed using GraphPad Prism 7. Data are expressed as 
mean ± SD. Significance was determined using Tukey’s multiple comparisons for all figures 
except for body weights, energy expenditures, RER, GTT area under the curve (AUC), and tissue 
triglycerides. For GTT AUC and tissue triglycerides, significance was determined using unpaired 
T-test.  A significance threshold of P < 0.05 was applied. For body weight, energy expenditure, 
and RER, discovery was determined by multiple T-tests using the two-stage linear step-up 
procedure of Benjamini, Krieger and Yekutieli, with Q = 1% (Benjamini, Krieger et al. 2006). 
Each row was analyzed individually, without assuming consistent SD.  
Results 
Niclosamide treated mice have lower Car3 protein expression 
In previous unpublished experiments, we observed that mice with fatty liver induced by 
diet-induced obesity (DIO) and treated with niclosamide had lower liver triglycerides and 
improved insulin sensitivity compared to untreated mice, which has been independently 
confirmed (Tao, Zhang et al. 2014). In an effort to identify which proteins might change in 
response to niclosamide treatment, we used 2D-DIGE analyses to compare liver protein 
expression from high-fat DIO treated with niclosamide or vehicle. Spots were then analyzed for 
differences in expression. One of the most abundant differentially expressed spot on the 2D-
DIGE gel was excised and identified as Car3 (Figure 3.2A). In order to verify that Car3 protein 
expression changed with niclosamide treatment, we performed western blots on liver lysates 
from additional DIO mice treated with vehicle, 5 mg/kg or 25 mg/kg body weight doses of 
niclosamide (Figure 3.2B). The western blots confirmed the 2D-DIGE results with high and low 
doses of niclosamide leading to lowered Car3 protein levels (standardized to actin) compared to 
the vehicle-treated mice (mean relative Car3 intensities of 1.56, 2.16 and 2.54 respectively).  
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Car3 is not required for de novo fatty acid synthesis 
 Given the correlation between Car3 expression and fatty liver we wondered whether Car3 
plays a role in lipid homeostasis. Given that bicarbonate is required for lipid synthesis, we tested 
the hypothesis that Car3 might be required for lipogenesis, using the radiolabeled-acetate 
incorporation assay to compare de novo fatty acid synthesis of wild type and Car3-/- primary 
mouse hepatocytes. Because the rate-limiting step of fatty acid synthesis requires bicarbonate 
(Figure 3.3A), we were concerned that traditional cell culture incubations utilizing a bicarbonate-
based buffering system would mask any potential differences in [1,2-14C]acetate incorporation 
into lipid. To account for this, we used L-15 media, a cell culture media with a bicarbonate-free 
buffering system, to culture and assay the hepatocytes. We also performed the assay in the 
presence and absence of carbon dioxide during incubation. For both with or without CO2, the 
incorporation of [1,2-14C]acetate into lipids was statistically indistinguishable between wild type 
and Car3 -/- cells. (Figure 3.3B) The incorporation of [14C]acetate into fatty acids was 65-67% 
higher in the hepatocytes incubated with 5% CO2, as expected, since that increases free 
bicarbonate in the media available for the first step in fatty acid synthesis (Figure 3.3A). These 
results indicate that Car3 expression has no significant affect on de novo lipogenesis in primary 
liver cells. Liver is the primary site of de novo lipogenesis in mammals. 
Weight gain, body composition, and chow consumption is not effected by Car3  
 To determine if Car3 affects body weight or composition, wild type and Car3 -/- mice 
were put on a high-fat diet (HFD) or standard chow at 5 weeks of age and measured once a week 
for 10 weeks. Body weights of wild type and Car3 -/- mice did not differ significantly at any age 
for either standard chow or high-fat diet (Figure 3.4A). After 8-9 weeks on the diets, food 
consumption was monitored over a pre-acclimated 24-hour period in a metabolic chamber 
  
46 
(Figure 3.4B). For both diets, Car3 did not effect food consumption. Wild type and Car3 -/- mice 
ate the same amount of standard chow or HFD during both the light and dark cycle. To see if fat 
and lean mass were individually affected, we measured body composition on standard chow and 
high-fat diet. The lean masses of wild type and Car3 -/- mice were not statistically different, with 
the overall mean at 22.85 ± 1.058g (Figure 3.4C). Similarly, fat masses of wild type and Car3 -/- 
mice were not significantly different, with overall mean fat mass on standard chow at 1.031 ± 
0.3721 and on high-fat diet at 7.729 ± 2.358 (Figure 3.4C). Mice on HFD had an increased 
contribution of fat mass compared to the mice on standard chow, as expected. These results 
suggest that Car3 is not affecting weight gain or fat and lean mass composition under ad libitum 
feeding conditions.     
Car3 has no significant affect on total energy expenditure or energy substrate utilization with 
standard chow or HFD fed mice 
 To determine if Car3 affects fuel source utilization, we measured total energy 
expenditure, energy substrate usage, and physical movement activity in metabolic chambers. 
Wild type and Car3 -/- mice on both diets showed no difference in activity or energy expenditure 
(Figure 3.5A). To measure contribution of lipids or carbohydrates to energy usage, respiratory 
exchange ratios (RER) were calculated for the wild type and Car3 -/- mice fed standard chow 
and HFD; an RER equal to 0.7 indicating fatty acid oxidation is the main source of energy, 
whereas an RER equal to 1.0 or greater indicates carbohydrates are the primary fuel source. Wild 
type and Car3 -/- mice have similar RER values throughout the 24-hour monitoring period, and 
the light and dark cycle values were not statistically different for either standard chow or HFD-
fed mice (Figure 3.5B). During both the light and dark cycle, there were also no significant 
differences in movement activity/average beam breaks for wild type and Car3 -/- mice fed 
standard chow or HFD (Figure 3.5C). 
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Car3 has no effect on HFD-induced insulin resistance 
Mice fed high-fat diets can have elevated fasting blood glucose and insulin reflecting 
lower insulin sensitivity (Wang and Liao 2012, Eisinger, Liebisch et al. 2014). To test the effect 
of Car3 on insulin sensitivity, we performed glucose tolerance tests (GTT) and collected fasting 
blood glucose and insulin on mice fed either standard chow or high-fat diet. Since liver Car3 
mRNA expression is highest in the fed state, to maximize possible differences between wild type 
and knockout mice, we also obtained fed blood measurements (Bauer, Hamm et al. 2004). Both 
wild type and Car3 -/- mice fed standard chow had lower blood glucose and insulin in the fasting 
state than in the fed state (as expected); similarly HFD-fed mice had elevated fasting blood 
glucose and insulin compared to standard chow fed mice (Figures 3.6A and 3.6B), as also 
expected. Glucose tolerance tests in mice fed standard chow and high-fat diet were not 
statistically significant between wild type and Car3 -/- mice in individual glucose measurements 
or area under the curve calculations (Figure 3.6C).  
Car3 knockouts have normal serum and tissue lipid/fatty acid biomarker levels 
To see if Car3 plays a role in increased liver triglycerides found in mice with fatty liver, 
we measured serum and tissue lipids (fatty acids and triglycerides). As stated previously, fed 
serum measurements were also obtained due to Car3 mRNA expression being highest in the liver 
in the fed state. Fasted and fed serum triglycerides, non-esterfied fatty acids (NEFA), cholesterol, 
and glycerol levels were all measured and found not statistically different between wild type and 
Car3 -/- mice on either diet (Figures 3.7A-3.7D). Liver and muscle triglyceride content also 
showed no difference between wild type and Car3 -/- mice (Figures 3.7E and 3.7F).  
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Is Car3 required for lipid uptake/mobilization during thermogenesis? 
Given the abundance of Car3 in adipose and skeletal muscle and increase in fatty livers, 
this was somewhat reminiscent of the expression of CD36 protein, which also increases in fatty 
liver and is abundant in adipose tissue (Koonen, Jacobs et al. 2007, Sheedfar, Sung et al. 2014).  
One of the most profound phenotypes of CD36 knockout mice is the inability to maintain core 
body temperature under cold challenge due to suspected inability to uptake lipid and 
subsequently hydrolyze it for energy/heat, particularly in brown fat (Bartelt, Bruns et al. 2011). 
Given the similarity in expression of CD36 and Car3 proteins in lipid-storing tissues, we 
subjected Car3 -/- mice to cold temperature challenge. Car3 -/- mice are not impaired in their 
ability to maintain core body temperature in the cold (Figure 3.8). 
Discussion 
Despite the abundance of Car3 in key metabolic tissues including white and brown fat, 
liver, and skeletal muscle its function remains unknown.  The relatively high abundance of Car3 
these tissues– in fats Car3 is nearly 30% of soluble protein and 8% in slow-twitch muscle 
(Lynch, Brennan et al. 1993, Kim, Lee et al. 2004)– led to extensive analysis of Car3 -/- muscle 
function but showed relatively mild muscle phenotypes with normal “growth, development and 
life span” (Kim, Lee et al. 2004). 
Although the exact function of Car3 remains unknown, many researchers postulate Car3 
function is not as a carbon dioxide hydratase given its relatively miniscule enzymatic activity 
compared to Car1 and Car2 (0.16% with purified protein in vitro (Nishimori, Minakuchi et al. 
2009)). Additional evidences suggesting Car3 may not function to produce bicarbonate in vivo 
are observations that the most potent Car3 inhibitor is carbonate ion (10µM KI), which is in 
equilibrium with bicarbonate itself (Nishimori, Minakuchi et al. 2009).  These investigators 
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stated “it is difficult to explain why Nature preserved … such a “bad” catalyst” that is also most 
potently inhibited by a proposed equilibrium product. 
Even though evidence suggests Car3 may have no functional role in producing 
bicarbonate, we still explored potential roles for Car3 in lipid homeostasis because Car3 protein 
is highly enriched in tissues that can accumulate or synthesize lipid, and because bicarbonate is 
essential for fatty acid synthesis (Alver, Ucar et al. 2004).  The three prior studies characterizing 
Car3 knockout mice did not investigate phenotypes related to lipid synthesis or storage nor did 
these studies feed high-fat diets to find any phenotypes (Kim, Lee et al. 2004, Liu, Walter et al. 
2007, Feng and Jin 2016).   
Although Car3 may not drive bicarbonate production in vivo, no one previously used 
Car3 -/- mice to demonstrate that Car3 is not required for de novo lipogenesis in vivo (Fig 3).  
Given the abundance of Car3 in lipid containing tissues, we decided to focus on the response of 
Car3 -/- mice fed a high-fat diet known to alter lipid homeostasis.  We measured key metabolic 
indicators including: weight gain, body composition, chow consumption, energy expenditure, 
insulin resistance, and dyslipidemia. Car3 deficiency had no affect on the biomarkers we tested, 
suggesting that Car3 is not responsible for the synthesis of fat nor does it affect the mobilization 
of fat in these tissues. 
We identified Car3 as a protein increased in the liver in a mouse model fed high-fat diet 
but lowered with niclosamide (Fig 2), a drug shown to improve fatty liver and T2D-like 
symptoms (Tao, Zhang et al. 2014).  Since Car3 liver protein expression was higher in DIO mice 
fed HFD, and lower in niclosamide treated HFD-fed DIO mice, we hypothesized that Car3 was 
involved in the development of fatty liver in this disease model. We saw no difference in liver 
triglycerides of wild type and Car3 -/- mice fed HFD, which suggests that Car3 is not required 
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for accumulation of fat in the liver. While Car3 could be a biomarker for fatty liver disease in 
DIO mice, it is also possible that the effect of decreased Car3 seen in niclosamide-treated mouse 
livers may simply reflect lower fat content in the tissue, without regulating its decrease.  
The high abundance of Car3 in selected tissues and relative lack of enzymatic activity 
suggest perhaps Car3 plays a non-enzymatic role.  There is evidence that Car3 acts as a 
protectant against oxidative damage; cells transfected with Car3 are protected from apoptosis 
induced by hydrogen peroxide (Raisanen, Lehenkari et al. 1999). Car3 can also undergo the 
posttranslational modification by S-glutathionylation at two cysteine residues, Cys186 and 
Cys181 not found in Car1/2 (Chai, Jung et al. 1991, Lii, Chai et al. 1994, Mallis, Poland et al. 
2000). S-glutathionylation of proteins is an early response to oxidative damage (Thomas, Poland 
et al. 1995). S-glutathionylation of Car3 increases with increased oxidative damage that occurs 
naturally as in aging (Cabiscol and Levine 1995) or with muscle damage (Zimmerman, Wang et 
al. 2004). Car3 contains numerous other additional cysteine residues not found in Car1/2. The 
concept of Car3 as an abundant “scavenging” protein to protect against oxidative damage is 
becoming an area of more research focus (Monti, De Simone et al. 2017). 
Interestingly, Car3 protein expression is altered in SOD1, copper zinc super oxide 
dismutase 1, providing another connection to oxidative stress responses in tissues.  In SOD1 -/- 
mouse knockouts Car3 protein was identified as an abundant oxidized protein in liver that 
decreases over time specifically in knockouts (Elchuri, Oberley et al. 2005). Similarly, in the 
‘toxic milk’ mouse mutant, Car3 protein is also greatly reduced in the liver; Car3 was shown to 
bind copper ions in addition to zinc (Grimes, Paynter et al. 1997). (Toxic milk protein is an 
ATP7B transporter that helps regulate copper levels in the body.)  Thus Car3 seems to have 
physiological connections to both metallic ions and oxidative stress responses.  While our study 
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has not demonstrated a role for Car3 in lipid metabolism, future characterization of Car3 -/- mice 
for roles in oxidative stress responses or for functions related to binding metal ions in cells may 
be more fruitful. 
Conclusion 
In conclusion, we attempted to determine the role of Car3 in lipid 
metabolism/homeostasis after we discovered Niclosamide decreased Car3 protein in the livers of 
HFD fed mice under similar conditions that improve fatty liver and insulin sensitivity/diabetic 
symptoms in mice (Tao, Zhang et al. 2014, Chowdhury, Turner et al. 2017). Since Niclosamide 
decreases liver triglycerides and improves insulin sensitivity, we hypothesized that perhaps Car3 
had a functional role in promoting fatty acid synthesis or lipid accumulation. We determined 
using mouse genetics that Car3 is not required for de novo lipogenesis. Additionally, we found 
that Car3 knockout and wild type mice fed either a standard chow or a HFD are not statistically 
different in weight, body composition, metabolic rate, insulin sensitivity, serum lipids, or tissue 
triglycerides. While Car3 is an abundant protein in many key metabolic tissues, the physiological 
role of Car3 in these tissues still remains to be determined.  
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Figure 3.1. Amino acid sequence alignment of cytosolic carbonic anhydrases reveals key 
enzyme amino acids changes that affect activity. CA III (Car3) amino acid alignment with 
carbonic anhydrase family members Car1 and Car2. Car3 shares a 57%/56% identity and 
74%/75% similarity with Car2 and Car1 respectively. Car3 has a 69% identity with either Car2 
or Car1. Amino acids highlighted in yellow are identical between the three CAs. Amino acids 
highlighted in orange are shared between Car3 and either Car1 or Car2. The active site of all 
carbonic anhydrases contain a Zn2+ and three histidine residues (highlighted in blue) (Nishimori, 
Minakuchi et al. 2007). Two key amino acid differences (highlighted in red), at Lys64 and 
Phe198, are responsible for the substantially lower rate of regeneration of the active form for 
carbonic anhydrase 3 compared to the other two CAs (LoGrasso, Tu et al. 1993, Tu, Chen et al. 
1994). A lysine at amino acid 64 results in a less effective proton shuttle, (An, Tu et al. 2002, 
Elder, Fisher et al. 2007) and Phe198 causes a steric hindrance at the active site (Duda, Tu et al. 
2005). 
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Figure 3.2. 2D-DIGE identifies Car3 as a protein with decreased expression in livers of 
high-fat diet fed mice treated with Niclosamide. (A) 2D-DIGE of liver lysates from 20 week-
old diet-induced obesity (DIO) mice treated with 10mg/kg niclosamide (green) or vehicle (red) 
for 12 days. Car3 protein is highlighted in the white circle. (B) Independent validation by 
Western blot analysis of Car3 from DIO mice treated with vehicle, low niclosamide (5mg/kg), or 
high niclosamide (25mg/kg) for 12 days. 
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Figure 3.3. Car3 is not required for de novo lipogenesis. (A) The rate-limiting step in fatty 
acid synthesis requires bicarbonate for the carboxylation of acetyl-CoA to malonyl-CoA by 
acetyl-CoA carboxylase (ACC). (B) Wild type (WT) and Car3 -/- (KO) hepatocytes show no 
difference in de novo lipogenesis. Hepatocytes were labeled with [1,2-14C] acetate in the 
presence and absence of carbon dioxide in bicarbonate free media. Data shown are from three 
experiments performed with six replicates.  
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Figure 3.4. Car3 -/- mice fed high-fat diet showed no difference in weight gain, food 
consumption, or body composition. (A) Weight gain of wild type (WT) and Car3 -/- (KO) 
mice fed normal chow (n=7-8) or high-fat diet (n=9) starting at 5 weeks of age. (B) Body 
composition, fat and lean mass, of wild type and Car3 -/- mice measured at 11 weeks old by 
MRI. (C) Chow consumption of mice fed standard chow (n=7-8) or high-fat diet (n=6) during 
light and dark cycle measured at 13-14 weeks old.  
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Figure 3.5. Car3 -/- mice show no changes in total energy expenditure, RER, or activity. 
Wild type (WT) and Car3 -/- (KO) energy expenditure (A), Respiratory Exchange Ratio (B), and 
activity (C) measured over a 24 hour period in 13-14-week-old mice on a standard chow (n=7-8) 
or high-fat diet (n=6). Standard chow fed to mice at weaning (3 weeks of age), mice fed high-fat 
diet were switched to HFD at 5 weeks of age. 
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Figure 3.6. Car3 -/- does not affect high-fat diet-induced insulin-resistance. Fasting and fed 
blood glucose (A) and serum insulin (B) from wild type (WT) and Car3 -/- (KO) mice fed 
standard chow (n=7-8) or high-fat diet (n=8-9) for 10 weeks. (C) Oral glucose tolerance test 
(with area under the curve below) performed on standard chow (n=7-8) and high-fat diet (n=4-5) 
mice after 11 weeks on the respective diet regime. 
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Figure 3.7. Car3 -/- mice show no difference in serum and tissue lipids and lipid substrates. 
Fasting and fed serum triglycerides (A), non-esterfied fatty acids (B), cholesterol (C), and 
glycerol (D) of wild type (WT) and Car3 -/- (KO) mice fed standard chow (n=7-8) or high-fat 
diet (n=8-9) for 10 weeks. Liver (E) and muscle (F) triglyceride content in mice fed standard 
chow (n=7-8) or high-fat diet (n=8) for 13 weeks.  
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Figure 3.8. Car3 -/- mice have normal thermoregulation. Wild type (WT) and knockout (KO) 
body temperatures of adult mice aged 8-15 weeks at different states of thermoregulation. Fasted 
state is an overnight fast for 15-18 hours. (A) Females fed standard chow (n=6-7). (B) Males fed 
HFD for 10 weeks, starting at age 5 weeks (n=8-9) (C) Females were fasted overnight and 
subjected to 4°C for 5 hours (n=3). 
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CHAPTER 4 – CONCLUSIONS & FUTURE DIRECTIONS FOR CA III STUDIES 
 
Conclusions 
 Role of CA III still unknown but future areas for exploration are more clear 
This dissertation investigated the function of CA III in lipid metabolism. We 
unfortunately did not find a genetic requirement for CA III in lipid synthesis. However, we made 
some progress in understanding mechanistic pathways CA III is not required for function. We 
observed that CA III protein expression decreases in livers of mice treated with niclosamide, a 
drug that improves insulin sensitivity and reduces liver triglycerides in HFD-induced fatty liver 
mice (Renner, Walker et al. 2017). Elevated CA III in untreated fatty livers was consistent with 
prior CA III expression data that showed CA III expression was high in nutrition rich states 
(mentioned in Chapter 2) and also indicated that CA III expression was correlated with the 
amount of lipid in liver. This implied a role for CA III in lipid metabolism, either through 
promoting de novo lipogenesis and/or lipid storage, or regulating lipid breakdown. 
We subsequently found that CA III is not required for de novo synthesis and a high-fat 
diet is not enough of a metabolic stressor to induce gross differences in lipid metabolism 
between Car3 WT and KO mice (Renner, Walker et al. 2017). Since we did not directly address 
lipid storage or lipolysis, more research is required to address CA III functionality in the 
progression of fatty liver disease and lipid metabolism. 
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Potential confounding variables  
Why we did not find significant differences in Car3 WT and KO mice  
We found no significant differences between Car3 WT and KO mice in any of the assays 
we performed: glucose tolerance, weight gain on different diets, liver triglycerides, metabolic 
chambers, or tissue weights (Renner, Walker et al. 2017). We cannot rule out the possibility that 
CA III is involved in lipid metabolism, rather it is possible the effects were too small to be 
reliably quantified or we were not directly testing the specific metabolic pathway affected by CA 
III. While we controlled for variables as much as possible, there are many confounding variables 
that could explain why we saw no significant differences between Car3 WT and KO mice: 
timing, temperature, lack of appropriate stressor, or genetic compensation.  
In humans and other animals, biological clocks, or circadian rhythms, anticipate and 
assist in the timing of important physiological functions like sleeping and eating through the 
regulation of hormones and metabolic pathways (Maury, Ramsey et al. 2010). To avoid 
disturbing the circadian rhythms, access to light is well regulated in mouse facilities with 12 
hours of daylight and 12 hours of darkness. Even though we controlled for blood and tissue 
collection time, it is possible we missed differences in metabolites due to the timing of peak 
circadian rhythm hormone/lipid/metabolite production (Kalsbeek and Strubbe 1998) (Maury, 
Ramsey et al. 2010) (Ferrell and Chiang 2015). Similarly, it is possible we missed minor 
differences in fasted metabolites by not optimizing the fasting duration. Metabolites and 
hormones are dynamically regulated and can significantly change depending on fasting duration 
(Geisler, Hepler et al. 2016). It is possible that there was a minor difference in glucose, fatty 
acids, or other metabolites tested in the blood that was unable to be seen during our experimental 
window.   
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The Car3 WT and KO mice were housed at room temperature (~20-23°C). While a 
commonly accepted practice, mice raised and studied below thermoneutral condition (~28-
30°C), can have altered metabolic phenotypes: impaired glucose homeostasis, higher oxygen 
consumption, and increased food consumption (Dudele, Rasmussen et al. 2015). Specifically, 
mice have a shivering mechanism independent of uncoupling, lipolysis, and fatty acid oxidation 
that can mask changes in these pathways when tested below thermoneutral conditions. For 
example, UCP1 KO mice were protected from obesity in initial studies done at room temperature 
due to the secondary shivering mechanism, however when studied in thermoneutral conditions, 
where the secondary mechanism would not be necessary the UCP1 KO mice gained more weight 
than UCP1 WT mice (Feldmann, Golozoubova et al. 2009). It is possible that differences in 
weight gain or lipid metabolism in the Car3 KO mice were masked by the secondary shivering 
mechanism.  
While duplicate mechanisms can compensate for alterations in metabolism, like the 
UCP1 KO mice, isozymes of the α-CA family can also potentially compensate for loss of CA III 
in mice. For example, studies previously mentioned in Chapter 1 with CA VA and VB single and 
double KO mice showed that CA VA could compensate for the loss of CA VB (Shah, Rubbelke 
et al. 2013). Additionally, humans deficient in CA I are able to compensate for this loss, as they 
have no disease phenotypes (Sly and Hu 1995). It is possible that there are unknown 
compensatory mechanisms in mice for CA III depletion that we were unaware of. Co-depletion 
of other similar enzymes with CA III may give us stronger disease phenotypes. A possible 
compensatory enzyme could be CA VII, as CA III and CA VII are the only CA isozymes that 
can be S-glutathionylated and they have a similar tissue distribution. 
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These studies were conducted using common experimental procedures in order to 
determine a disease phenotype of CA III and to help elucidate a role for CA III in metabolism. It 
is possible that the role of CA III in metabolism is subtle and therefore requires a more detailed 
exploration of phenotypes. Future studies using CA III KO mice should consider a more detailed 
procedure with stricter phenotypic analysis and consider focusing more strongly on the following 
experimental procedures: careful and precise timing of blood draws and tissue extractions, 
stricter control of temperature, and potentially utilizing double knockout mice in order to test for 
compensatory mechanisms of CA III with other carbonic anhydrases.  
Future directions 
CA III expression and regulation in fatty liver disease 
CA III expression data previously indicated a decrease in CA III protein and mRNA 
when fatty liver is induced with particular mouse models: alcohol, methionine deficient diets, 
and carbon tetrachloride (Aroor, Roy et al. 2012) (Ronchi, Conde et al. 2004, Kharbanda, 
Vigneswara et al. 2009, Yamada, Satoh et al. 2013, Carter, Vigneswara et al. 2015) (Sanllorenti, 
Rosenfeld et al. 2001, Henkel, Roderfeld et al. 2006, Wong, Fan et al. 2011, Eakins, Walsh et al. 
2015). These results implied that CA III was protecting the liver from oxidative damage and the 
decrease in CA III contributed to the diseased livers. However, our data suggested that CA III 
was elevated in HFD-induced fatty livers and perhaps promoted the accumulation of fat in livers 
(Renner, Walker et al. 2017). As discussed earlier in Chapter 2, fatty liver disease progression is 
thought to have three stages: fat accumulation, inflammation and oxidative damage, and lastly 
fibrosis and death of the liver. The fatty liver disease model we used, HFD-induced, contributes 
to the first stage of fat accumulation whereas alcohol, methionine deficient diets, and carbon 
tetrachloride also directly contribute to the later stage of inflammation and oxidative damage 
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(Anstee and Goldin 2006, Lau, Zhang et al. 2017). HFD indirectly induces oxidative damage as 
it causes obesity and dyslipidemia, which contribute to the induction of oxidative stress 
(Hutcheson and Rocic 2012). Enzymes critical for dealing with reactive oxygen species (ROS) 
are down regulated during oxidative damage (Hutcheson and Rocic 2012), and the subsequent 
increased ROS production damages phospholipid membranes of organelles, increases lipid 
peroxidation, and releases pro-inflammatory cytokines (Anstee and Goldin 2006, Le Lay, Simard 
et al. 2014). While we do not fully understand the role of CA III in fatty liver disease, we 
speculate that CA III either promotes a lipid storage/accumulation pathway that is down-
regulated with increased ROS, or CA III protects the liver against oxidative damage under 
normal conditions and increased ROS decreased the expression of CA III.  
Measuring CA III protein modification by oxidative stress and metabolism 
 A majority of our research focused on lipid metabolism, however we wanted to address 
the possibility that CA III might be protecting livers from oxidative damage. We found no 
difference in oxidation of proteins in livers of Car3 WT and KO mice under diverse metabolic 
conditions: fed different diets and under starved conditions (Figure 4.1). Our result suggested 
that CA III is not required for oxidative stress response, although lipid peroxidation products and 
other indicators of oxidative damage were not tested.  
 While Car3 KO mice showed no differences in response to oxidative damage, our 
experimentation was not exhaustive. The understanding of CA III and its role in oxidative 
damage is very basic; it can be S-glutathionylated and its expression is decreased during 
oxidative stress. Instead of characterizing the phenotypes of CA III mice, further experiments 
should focus why CA III expression decreases during oxidation. One possibility is that CA III is 
not as stable when oxidized. To test if CA III protein stability is affected by oxidative damage 
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through S-glutathionylation, we could perform 35S-radiolabeled amino acid pulse-chase analysis 
under normal and oxidized conditions in cell lines that express CA III, like differentiated 3T3-L1 
or sol8 (Zhou 2004). By comparing the half-life of CA III under oxidized and non-oxidized 
conditions, we should be able to determine if protein turnover is directly affected by oxidation. 
Additionally, we can use isoelectric focusing to visualize differences in S-glutathionylation 
during protein-turnover and oxidative damage (Chai, Jung et al. 1991). We could also 
experiment with inhibiting or reversing S-glutathionylation, by incubating cells with and without 
an abundance of glutathione (which reverses S-glutathionylation of CA III). This could help us 
determine if this post-translational modification effects CA III protein stabilization (Chai, Jung et 
al. 1991).  
Determining if CA III negatively regulates lipolysis  
From our finding that CA III protein is decreased in livers treated with niclosamide in 
mice, we speculated that CA III could be promoting oxidative damage response, or altering lipid 
metabolism either by promoting de novo lipogenesis and fat storage, or inhibiting lipolysis. We 
anticipated that deficiencies in lipid metabolism would have been detectable in our varied assays, 
yet we saw no difference in Car3 WT and KO mice (Renner, Walker et al. 2017). The assays 
used did not directly examine the hypothesis that CA III inhibits lipolysis, the degradation of 
triglycerides into fatty acids and glycerol. 
To test if CA III is involved in the signaling pathways for lipolysis, we could induce 
lipolysis in Car3 WT and KO primary cells, tissues, or in vivo with isoproterenol or another β-
adrenergic agonist and measure the products of TG breakdown (fatty acids and glycerol) 
(Rutkowski, Stern et al. 2015). Elevated products of lipolysis in Car3 KO mice would confirm a 
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role for CA III in regulating lipolysis. If there were a difference in lipolysis, further 
experimentation would be required to determine the regulatory mechanism.   
Understanding role of CA III in lipid droplets 
Lipolysis occurs on the membranes of lipid droplets (LDs) in cells. Lipid droplets are 
organelles composed of neutral fats—triglycerides and sterol esters—incased in a phospholipid 
monolayer (Walther and Farese 2012). Proteins associated with LDs can alter storage capacity 
and stability of LDs (Barneda and Christian 2017) (Walther and Farese 2012). Many lipid 
droplet-associated proteins are involved in regulating lipolysis, the breakdown of triglycerides 
into fatty acids and glycerol (Rutkowski, Stern et al. 2015). 
 CA III protein has been found in many different purified lipid droplet isolations from 
hepatocytes and adipocytes of rodents (Kanshin, Wang et al. 2009) (Ding, Wu et al. 2012) 
(Crunk, Monks et al. 2013, Khan, Wollaston-Hayden et al. 2015). While it is possible that CA III 
is so abundant in the cytosol that it contaminates the LD layers in isolations, the association with 
LDs seems plausible. As a negative control, lipid droplets fractions were probed for many 
abundant proteins in the cytosol, cell membranes, and mitochondria. The abundant cytosolic 
proteins, GAPDH and actin, were not found in the LD fractions (Kanshin, Wang et al. 2009) 
(Ding, Wu et al. 2012) (Khan, Wollaston-Hayden et al. 2015). Determining how CA III is 
associated with lipid droplets would verify the studies that found CA III in the lipid droplet 
proteome.    
LD associated proteins typically interact with the monolayer membrane in a variety of 
methods (Walther 2012); CA III likely associates with LDs binding to lipids or proteins that bind 
to the membrane. CA III has the potential to bind to lipids; the catalytic mechanism of carbonic 
anhydrase includes a stage in which a carboxyl group is bound to the active site. Since CA III 
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has alterations in amino acids near its active site compared to other cytosolic α-CAs, it is 
possible that instead of catalyzing the carboxylation of water CA III binds to the carboxyl groups 
of fatty acids, especially small chain fatty acids (Figure 4.2) (Supuran 2008). Lipid interactions 
with CA III could help explain how CA III associates with LDs, however CA III could also 
simply bind a protein already bound to the LD membrane.  
To determine if CA III binds to fatty acids or other lipids, we could affinity purify CA III 
from adipose cell or tissue lysates, extract bound lipids, and send to liquid chromatography mass 
spectroscopy following similar methodologies as Li et al. that found lipids and metabolites 
which bind to proteins (Li, Gianoulis et al. 2010). By adjusting the buffer utilized, protein-
protein interactions could also be measured using immunoprecipitation. It would be interesting to 
find any protein-protein interactions, not only to potentially determine how CA III associates 
with LDs but interactions could identify pathways that could guide future experiments to 
determine CA III functionality.  
Preliminary data- Car3 KO mice have increased water intake during night starvation 
In our published data, we were unable to find significant differences between Car3 WT 
and KO mice fuel utilization under fed conditions. However, an experiment performed during 
the writing of this document showed that fasted Car3 KO mice drank nearly twice as much water 
overnight compared to Car3 WT (Figure 4.3). This change was only seen during dark cycle of 
the fasted state, and there were no genotype differences in body weight, RER, energy 
expenditure, or movement.  
We made efforts to reproduce the drinking phenomenon without using the metabolic 
chamber, however this method was too crude, and measurements were inaccurate due to leakage 
of the generic animal facility water bottles. Additionally, the writing of this document and 
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wrapping up the CA III project prevented further follow up. While this experiment was not 
replicated, we thought its inclusion in this dissertation was important to illustrate a striking 
phenotype in the Car3 WT and KO mice that has never before been detected.  
The increased water intake in Car3 KO mice is puzzling, as it is not intuitive what 
drinking behavior has to do with CA III. Assuming the data replicate, there are three plausible 
hypotheses that could explain the increase in water consumption: 1) water is elevated to excrete a 
metabolite that accumulates in Car3 KO mice, 2) thirst is somehow regulated by CA III, 3) 
starvation and introduction to a new environment elevates stress hormones that affect drinking 
differentially in Car3 KO mice.  
Water is required to excrete wastes in urine. If the concentration of waste metabolites is 
greater than normal, more water is required to flush the kidneys to remove these compounds 
(Choi, Park et al. 2015). The CA III deficiency could be triggering an accumulation of waste, 
which could be a number of different compounds: sugars, urea, salts, or toxins (Bouatra, Aziat et 
al. 2013). Narrowing down potential pathways would be purely speculative without knowing if 
there is an increase in urine production. To determine if Car3 KO mice are drinking more 
because they are flushing a waste compounds in the urine, urine production of starved Car3 WT 
and KO mice should be measured and collected urine sent for metabolomic analysis (Bouatra, 
Aziat et al. 2013).  
Water intake is mostly regulated though osmotic pressure and sodium-sensitive receptors 
in the brain (Fuller 1984) (Popkin, D'Anci et al. 2010). In response to osmotic pressure, the thirst 
hormone, arginine vasopressin is elevated and induces thirst (Popkin, D'Anci et al. 2010). Some 
hormones not typically involved in regulating water intake can also increase water consumption; 
elevated cortisol and epinephrine, a glucocorticoid and catecholamine respectively, have been 
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shown to increase water intake (Katovich and Fregly 1978, Fuller 1984, Johnson, Beltz et al. 
2015). It is possible that Car3 KO mice have elevated thirst-inducing hormones while fasting, 
which causes these mice to consume more water.  
In addition to regulating water intake, vasopressin, insulin, glucocorticoids, and 
catecholamines all respond to stressful conditions (Ranabir and Reetu 2011). The Car3 WT and 
KO mice were subjected to two potential stressors, starvation and a new environment, that could 
have induced a more potent stress response in Car3 KO mice than the WT mice. To determine if 
Car3 KO mice are drinking more water through alterations in the water intake pathway or as a 
response to stress would require further testing. Basal and fasted hormones associated with water 
intake, arginine vasopressin, glucocorticoids, and catecholamines should be tested in blood and 
tissues from the Car3 WT and KO mice. This assay would determine if there are any differences 
in hormonal regulation of water intake or stress response and help define further exploration of 
CA III in either water intake pathways or responses to acute stress. 
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Figure 4.1. CA III has no effect on oxidation of proteins in livers of mice. Oxidized proteins 
from liver lysates of fed and fasted Car3 WT and KO mice. Liver lysates were DNP-derivatized, 
which marks the carbonyl groups of proteins and is an indicator of oxidative protein 
modification. (Abcam Oxidized Protein Western (ab178020)).  
  
  
75 
 
 
Figure 4.2. Potential binding of CA with carboxyl groups of lipids.  (A) CAs bind 
bicarbonate which contains a carboxyl group during catalysis. (B) Single fatty acids and fatty 
acids bound to glyceride backbones both have carboxyl groups that could bind to the active site 
of CA.   
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Figure 4.3. Car3 -/- mice drink more water than WT mice when fasting. Fasted female mice 
(n=4) were starved at 3pm. Fed male mice (n=7-8) had ad libitum access to standard chow and 
water.  
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